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The primary purpose of the National Antimicrobial Resistance Monitoring System (NARMS) at the Centers for 
Disease Control and Prevention (CDC) is to monitor antimicrobial resistance among enteric bacteria isolated from 
humans. Other components of the interagency NARMS program include surveillance for resistance in enteric 
bacteria isolated from foods, conducted by the U.S. Food and Drug Administration’s Center for Veterinary 
Medicine (FDA-CVM) 
(http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMoni
toringSystem/default.htm), and for resistance in enteric bacteria isolated from animals, conducted by the U.S. 
Department of Agriculture’s Agricultural Research Service (USDA-ARS) 
(http://www.ars.usda.gov/main/site_main.htm?modecode=66-12-05-08).  
 
Many NARMS activities are conducted within the framework of the Foodborne Diseases Active Surveillance 
Network (FoodNet), which is part of CDC’s Emerging Infections Program (EIP), and also with CDC’s 
Epidemiology and Laboratory Capacity (ELC) Program. In addition to surveillance of resistance in enteric 
pathogens, the NARMS program at CDC also conducts research into the mechanisms of resistance and performs 
susceptibility testing of isolates that caused outbreaks. 
 
Before NARMS was established, CDC monitored antimicrobial resistance in Salmonella, Shigella, and 
Campylobacter through periodic surveys of isolates from a panel of sentinel counties. NARMS at CDC began in 
1996 with prospective monitoring of antimicrobial resistance among clinical non-Typhi Salmonella (refers to all 
serotypes other than Typhi, which causes typhoid fever) and Escherichia coli O157 isolates in 14 sites. In 1997, 
testing of clinical Campylobacter isolates was initiated in the five sites participating in FoodNet. Testing of clinical 
Salmonella enterica serotype Typhi and Shigella isolates was added in 1999. Since 2003, all 50 states have been 
forwarding all Salmonella ser. Typhi isolates and a representative sample of non-Typhi Salmonella, Shigella, and 
E. coli O157 isolates to NARMS for antimicrobial susceptibility testing, and 10 FoodNet states have been 
participating in Campylobacter surveillance. Since 2008, all 50 states have been forwarding every Salmonella 
Paratyphi A and C to NARMS for antimicrobial susceptibility testing. Beginning in 2009, NARMS also performed 
susceptibility testing on isolates of Vibrio species other than V. cholerae. NARMS participating public health 
laboratories were asked to forward every isolate of Vibrio species other than V. cholerae that they received to 
CDC for antimicrobial susceptibility testing.  
 
This annual report includes CDC’s surveillance data for 2011 for non-typhoidal Salmonella, typhoidal Salmonella, 
Shigella, Campylobacter, E. coli O157, and Vibrio species other than V. cholerae. Surveillance data include the 
number of isolates tested by NARMS for each pathogen, and the number and percentage of isolates that were 
resistant to each of the antimicrobial agents tested. Data for earlier years are presented in tables and graphs 
when appropriate. Antimicrobial classes defined by the Clinical and Laboratory Standards Institute (CLSI) are 
used in data presentation and analysis.   
 
This report uses the World Health Organization’s categorization of antimicrobials of critical importance to human 
medicine (Appendix A) in the tables that present minimum inhibitory concentration (MIC) and percent resistant 
tables.  
 
Additional NARMS data and more information about NARMS activities are available at http://www.cdc.gov/narms/. 
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Azithromycin Susceptibility Data for E. coli O157, Salmonella and Shigella 
 
For the first time, we present azithromycin susceptibility data for Escherichia coli O157, Shigella, and Salmonella.  
Currently, azithromycin is recommended for the treatment of both shigellosis and invasive salmonellosis by the 
World Health Organization and The American Academy of Pediatrics, and this drug is increasingly being used for 
the management of uncomplicated enteric fever
 
(World Health Organization, 2005; American Academy of 
Pediatrics, 2012) At present, no CLSI clinical azithromycin breakpoints have been defined for Enterobacteriaceae, 
including Salmonella and Shigella. The azithromycin breakpoints used in this report are based on epidemiological 
cut-offs determined from NARMS MIC distributions of Salmonella and Shigella (Sjölund-Karlsson et al, 2011; 
Howie at al 2010). It should be noted that these NARMS-developed breakpoints cannot be used to predict clinical 
efficacy. Azithromycin replaced the aminoglycoside amikacin on the panel of drugs being tested, so only historical 
susceptibility data are provided for amikacin. 
 
Fluoroquinolone Breakpoints for Enterobacteriaceae 
 
In 2012, CLSI revised the fluoroquinolone interpretive criteria for invasive Salmonella. In our 2010 report, 
fluoroquinolone susceptibility data using both the outgoing and new breakpoints were reported. In this report, all 
interpretations are based on the new breakpoints published in the January 2012 CLSI M100 document. For public 
health surveillance purposes, the new breakpoints were applied to all Salmonella isolates (not just those from 
sterile sites) because all Salmonella serotypes have the potential to cause invasive infection. 
 
Testing of Ceftriaxone/Ceftiofur-Resistant Non-Typhoidal Salmonella for Resistance to Additional Broad-
Spectrum β-lactams 
 
Starting in 2011, all non-typhoidal Salmonella isolates displaying resistance to the third-generation cephalosporins 
ceftriaxone (MIC ≥4 μg/mL) or ceftiofur (MIC ≥8 μg/mL) were subjected to additional testing. Results for six broad-
spectrum β-lactam drugs, including aztreonam, cefepime, cefotaxime, ceftazidime, imipenem, and piperacillin-
tazobactam are reported. The results are presented on page 15. 
 
  
What is New in the NARMS Report for 2011 
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Population  
 
In 2011, all 50 states and the District of Columbia participated in NARMS, representing the entire U.S. population 
of approximately 312 million persons (Table 1). Surveillance was conducted in all states for Salmonella (typhoidal 
and non-typhoidal), Shigella, Escherichia coli O157, and Vibrio species other than V. cholerae. For 
Campylobacter, surveillance was conducted in 10 states that comprise the Foodborne Diseases Active 
Surveillance Network (FoodNet), representing approximately 48 million persons (15% of the U.S. population).  
 
Clinically Important Antimicrobial Resistance Patterns 
 
In the United States, fluoroquinolones (e.g., ciprofloxacin) and third-generation cephalosporins (e.g., ceftriaxone) 
are commonly used to treat severe Salmonella infections, including those caused by Salmonella ser. Typhi, the 
organism that causes typhoid fever. In Enterobacteriaceae, resistance to nalidixic acid, an elementary quinolone, 
correlates with decreased susceptibility to ciprofloxacin (MIC≥0.12 µg/mL) and possible fluoroquinolone treatment 
failure. Macrolides (e.g., azithromycin) are also of clinical importance. A substantial proportion of 
Enterobacteriaceae isolates tested in 2011 demonstrated clinically important resistance. 
 
Among Salmonella isolates, antimicrobial resistance varies by serotype. Changes in resistance among all non-
typhoidal Salmonella may reflect changes in resistance within serotypes, changes in serotype distribution, or both.   
 2.4% (57/2344) of non-typhoidal Salmonella isolates were resistant to nalidixic acid. Enteriditis was the most 
common serotype among nalidixic acid-resistant non-typhoidal Salmonella isolates.   
o 49% (28/57) of nalidixic acid-resistant isolates were ser. Enteriditis 
o 7.2% (28/391) of ser. Enteriditis isolates were resistant to nalidixic acid 
 2.5% (58/2344) of non-typhoidal Salmonella isolates were resistant to ceftriaxone. The most common 
serotypes among the 58 ceftriaxone-resistant isolates were Typhimurium, Newport, and Heidelberg.  
Resistance was detected in  
o 6.8% (22/323) of ser. Typhimurium isolates 
o 3.9% (11/285) of ser. Newport isolates 
o 8.6% (6/70) of ser. Heidelberg isolates 
 0.2% (5/2344) of non-typhoidal Salmonella isolates were resistant to azithromycin. 
 71% (271/383) of Salmonella ser. Typhi isolates were resistant to nalidixic acid and 7.3% (28/383) were 
resistant to ciprofloxacin. 
 97% (141/146) of Salmonella ser. Paratyphi A isolates were resistant to nalidixic acid and 2.1% (3/146) were 
resistant to ciprofloxacin. 
 
In Shigella, fluoroquinolones and macrolides (e.g., azithromycin) are important agents in the treatment of severe 
infections. 
 2.4% (7/293) of Shigella isolates were resistant to ciprofloxacin, including 
o 6.9% (4/58) of Shigella flexneri isolates 
 6.1% (18/293) of Shigella isolates were resistant to nalidixic acid, including 
o 12% (7/58) of Shigella flexneri isolates 
 3.1% (9/293) of Shigella isolates were resistant to azithromycin, including 
o 10% (6/58) of Shigella flexneri isolates 
o 0.9% (2/225) of Shigella sonnei isolates 
 
In Campylobacter, fluoroquinolones and macrolides (e.g., erythromycin) are important agents in the treatment of 
severe infections. Gentamicin is less commonly used for treatment.  
 24% (357/1478) of Campylobacter isolates were resistant to ciprofloxacin, including 
o 24% (299/1275) of Campylobacter jejuni isolates 
o 36% (53/148) of Campylobacter coli isolates 
 1.8%  (27/1478) of Campylobacter isolates were resistant to erythromycin, including  
o 1.7% (22/1275) of Campylobacter jejuni isolates 
o 2.7% (4/148) of Campylobacter coli isolates 
 2.0% (30/1478) of Campylobacter isolates were resistant to gentamicin, including 
o 12% (18/148) of Campylobacter coli isolates  
Summary of NARMS 2011 Surveillance Data 
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Multidrug Resistance 
 
Multidrug resistance is reported in NARMS in different ways, including resistance to multiple classes of 
antimicrobial agents and also by specific co-resistance phenotypes. 
 
For non-typhoidal Salmonella, an important multidrug-resistance phenotype includes resistance to at least 
ampicillin, chloramphenicol, streptomycin, sulfonamide (sulfamethoxazole/sulfisoxazole), and tetracycline 
(ACSSuT); these agents encompass five CLSI classes. Another important phenotype includes resistance to at 
least ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and 
ceftriaxone (ACSSuTAuCX); these agents encompass seven CLSI classes.  
 9.1% (213/2344) of non-typhoidal Salmonella isolates were resistant to three or more CLSI classes. The most 
common serotypes with this resistance pattern were Typhimurium, I,4,[5],12:i:, Heidelberg, Newport, 
Enteritidis, and Dublin. Resistance to three or more classes occurred in 
o 26% (85/323) ser. Typhimurium isolates  
o 27% (22/82) ser. I,4,[5],12:i:- isolates 
o 30% (21/70) ser. Heidelberg isolates  
o 3.9% (11/285) ser. Newport isolates 
o 2.3% (9/391) ser. Enteriditis isolates  
o 60% (6/10) ser. Dublin isolates 
 
 1.5% (36/2344) of non-typhoidal Salmonella isolates were at least ACSSuTAuCx resistant.  The most 
common serotypes were Typhimurium, Newport, and Dublin.  ACSSuTAuCx resistance occurred in  
o 5.3% (17/323) ser. Typhimurium isolates  
o 3.5% (10/285) ser. Newport isolates 
o 40.0% (4/10) ser. Dublin isolates 
 
For Salmonella ser. Typhi, an important multidrug-resistance phenotype includes resistance to at least ampicillin, 
chloramphenicol, and trimethoprim-sulfamethoxazole (ACT/S). 
 10.4% (40/383) of ser. Typhi isolates were resistant to at least ACT/S and 12.3% (47/383) were resistant to 
three or more classes  
 
For Shigella, an important multidrug-resistance phenotype includes resistance to at least ampicillin and 
trimethoprim-sulfamethoxazole (AT/S). 
 26% (76/293) of Shigella isolates were resistant to at least AT/S and 51% (150/293) were resistant to three or 
more classes 
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Changes in Antimicrobial Resistance: 2011 vs. 2003–2007 
 
To understand changes in the prevalence of antimicrobial resistance among Salmonella, Shigella, and Campylobacter over time, we used 
logistic regression to compare the prevalence of specific resistance patterns among isolates tested in 2011 with the average prevalence of 
resistance in 2003–2007. The prevalence of resistance was defined as the percentage of resistant isolates among total isolates tested. The 
methods are described in more detail in Surveillance and Laboratory Testing Methods. Changes in the prevalence of resistance do not provide 
information about changes in the incidence of resistant infections. The incidence and relative changes in the incidence of Salmonella, Shigella, 
and Campylobacter infections are reported annually from surveillance in FoodNet sites (CDC, 2012). Since 2003, all 50 states have 
participated in NARMS Salmonella and Shigella surveillance and all 10 FoodNet sites in Campylobacter surveillance.   
 
The differences between the prevalence of resistance in 2011 and the average prevalence of resistance in 2003–2007 (Figure 1) were 
statistically significant for the following: 
 Among non-typhoidal Salmonella 
o Resistance to one or more CLSI classes was lower  in 2011 than in 2003–2007 (15.4% vs. 19.9%; odds ratio [OR]=0.78, 95% 
confidence interval [CI] 0.69–0.88) 
o Resistance to three or more CLSI classes was lower in 2011 than in 2003–2007 (9.1% vs. 12.1%; OR=0.77, 95% CI 0.66–0.90) 
 Among Salmonella of particular serotypes 
o ACSSuTAuCx resistance in  ser. Newport was lower in 2011 than in  2003–2007 (3.5% vs. 13.4%; OR=0.30, 95% CI 0.15–0.59) 
o Nalidixic acid resistance in ser. Typhi was higher in 2011 than in 2003–2007 (70.8% vs. 48.9%; OR=2.56, 95% CI 2.01–3.27) 
 Among Shigella spp. 
o Nalidixic acid resistance was higher in 2011 than in 2003–2007 (6.1% vs. 1.9%; OR=3.61, 95% CI 1.98–6.55) 
 Among Campylobacter spp. 
o Ciprofloxacin resistance was higher in 2011 than in 2003–2007 (24.2% vs. 20.8%; OR=1.19, 95% CI 1.02–1.39) 
 
The differences between the prevalence of resistance in 2011 and the average prevalence of resistance in 2003–2007 (Figure 1) were not 
statistically significant for the following: 
 Among non-typhoidal Salmonella  
o Ceftriaxone resistance (2.5% vs. 3.5%; OR=0.78, 95% CI 0.58–1.03) 
o Nalidixic acid resistance (2.4% vs. 2.1%; OR=1.25, 95% CI 0.93–1.69) 
 Among Salmonella of particular serotypes 
o Nalidixic acid resistance in ser. Enteritidis (7.2% vs. 5.8%; OR=1.30, 95% CI 0.84–2.03) 
o ACSSuT resistance in ser. Typhimurium (19.5% vs. 22.9%; OR=0.83, 95% CI 0.61–1.11) 
o Ceftriaxone resistance in ser. Heidelberg (8.6% vs. 7.9%; OR=1.19, 95% CI  0.48–2.96) 
 Among Campylobacter jejuni, ciprofloxacin resistance  (23.5% vs. 20.4%; OR=1.18, 95% CI 1.00–1.40) 
 
Figure H1.  Summary of trend analysis of the prevalence of specific resistance patterns among Salmonella, Shigella, and 
Campylobacter isolates, 2011 compared with 2003–2007* 
 
 
  
 
*   The reference is the average prevalence of resistance in 2003–2007. Logistic regression models adjusted for site. The odds ratios (ORs) and 95% confidence intervals (CIs) for 2011   
    compared with the reference were calculated using unconditional maximum likelihood estimation. ORs that do not include 1.00 in the 95% CIs are reported as statistically significant.  
    California may have submitted more than 1 in 20 non-typhoidal Salmonella isolates from 3 counties during 2008–09; however, analysis excluding isolates from those counties showed       
    equivalent results. 
†  Antimicrobial classes of agents defined by the Clinical and Laboratory Standards Institute (CLSI) are used 
‡  ACSSuT:resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline  
§  ACSSuTAuCx: resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone 
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Testing of Ceftriaxone/Ceftiofur Resistant Non-Typhoidal Salmonella to Additional Broad-
Spectrum β-Lactams, 2011 
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Among 2,344 isolates of non-typhoidal Salmonella collected by NARMS in 2011, 58 displayed resistance to the 
third-generation cephalosporins ceftriaxone (MIC ≥4 μg/mL) or ceftiofur (MIC ≥8 μg/mL). The antimicrobial 
susceptibility patterns of these isolates were further investigated by determining the MICs to additional β-lactam 
drugs. Results are reported for six additional β-lactam drugs (aztreonam, cefepime, ceftazidime, cefotaxime, 
piperacillin-tazobactam, and imipenem). Susceptibility testing was performed using broth microdilution 
(Sensititre®, Trek Diagnostics, Cleveland, OH) according to the manufacturer’s instructions. 
 
Among the 58 isolates tested, 6 (10.3%) showed resistance to the β-lactam/β-lactamase inhibitor combination 
piperacillin-tazobactam. In the cephem class, 1 (1.7%) was resistant to cefipime, all 58 to cefotaxime, and 56 
(97%) ceftazidime. Twenty-four (41%) were resistant to the monobactam aztreonam and 1 (1.7%) to the penem 
imipenem. 
 
A single isolate, ser. Senftenberg, displayed resistance to the carbapenem imipenem (MIC 4 μg/mL). The same 
isolate also displayed elevated MICs to the other drugs tested (aztreonam MIC >32 μg/mL, cefepime MIC >32 
μg/mL, ceftazidime MIC >128 μg/mL, cefotaxime >128 μg/mL, and piperacillin-tazobactam MIC >128 μg/mL).  
Molecular characterization of this isolate revealed the presence of a gene encoding a New Delhi metallo-β-
lactamase (NDM) carbapenemase, as well as two additional β-lactamase genes (blaTEM and blaCMY classes of 
genes). A NDM carbapenemase was first described by Yong et al. in 2009 and has been detected in other clinical 
isolates of Enterobacteriaceae in the United States.
1,2,3
 The present isolate represents the first NDM-positive 
Salmonella identified in the United States and has been described in a previous report.
2
 The detection of a NDM 
carbapenemase in Salmonella highlights the continued need for and importance of performing additional testing 
against broad-spectrum β-lactam drugs. 
 
Table H1. Broad-spectrum β-lactam resistance among all ceftriaxone/ceftiofur-resistant non-typhoidal Salmonella 
isolates, 2011 (N=58)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
β-lactam / β-lactamase 
inhibitor combinations
Piperacillin-
tazobactam
15.5 10.3 [3.9 - 21.2] 1.7 5.2 15.5 39.7 12.1 5.2 10.3 3.4 6.9
Cephems Cefepime 0.0 1.7 [0.0 - 9.2] 3.4 32.8 41.4 13.8 5.2 1.7 1.7
Cefotaxime 0.0 100 [93.8 - 100] 1.7 10.3 37.9 34.5 10.3 3.4 1.7
Ceftazidime 3.4 96.6 [88.1 - 99.6] 3.4 22.4 53.4 12.1 6.9 1.7
Monobactams Aztreonam 43.1 41.4 [28.6 - 55.1] 6.9 8.6 43.1 27.6 8.6 5.2
Penems Imipenem 0.0 1.7 [0.0 - 9.2] 1.7 77.6 19.0 1.7
*
†
‡
§
¶
**
Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate 
breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the 
low est tested concentrations represent the percentages of isolates w ith MICs equal to or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank *
CLSI† Antimicrobial 
Class
Antimicrobial 
Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
I
  
                                                          
1
 Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. Characterization of a new metallo-beta-lactamase gene, bla(NDM-    
    1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.  
    Antimicrob Agents Chemother. 2009 Dec;53(12):5046-54. 
 
2
 Savard P, Gopinath R, Zhu W, Kitchel BJ, Rasheed K, Tekle T, Roberts A, Ross T, Razeq J, B. Landrum BM,  Wilson LE, Limbago B, Perl  
   TM, and Carroll KC. First NDM-Positive Salmonella sp. Strain Identified in the United States. Antimicrob Agents Chemother. 2011 Dec;  
   55(12): 5957–5958. 
 
3
 Mochon AB,  Garner OB,  Hindler JA, Krogstad P,  Ward KW, Lewinski MA,  Rasheed JK,  Anderson KF,  Limbago BM, and Humphries RM.   
    New Delhi Metallo-β-Lactamase (NDM-1)-Producing Klebsiella pneumoniae: Case Report and Laboratory Detection Strategies. J Clin  
    Microbiol. 2011 April; 49(4): 1667–1670. 
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Emergence of ASSuT Resistance in Salmonella ser. I 4,[5],12:i:- in the United States 
Over the last 10 years, a notable increase of Salmonella ser. I 4,[5],12:i:- infections with resistance to ampicillin, 
streptomycin, sulfonamide, and tetracycline (ASSuT) but not chloramphenicol, has been observed throughout 
Europe. Serotype I 4,[5],12:i:- is related to serotype Typhimurium (I 4,[5],12:i:1,2). Resistance is conferred by 
blaTEM, strA/B, sul2, and tet(B) genes on the chromosome.
1,2
 In the United States, ASSuT resistance among 
human Salmonella ser. I 4,[5],12:i:- isolates emerged in 2010; thirteen (17%) of 78 isolates in NARMS had this 
resistance pattern in 2010 compared with 1 (1.4%) of 72 in 2009 (Figure H2 and Table H2).   Resistance to 
ampicillin, streptomycin, sulfonamide, and tetracycline has also been observed among NARMS isolates of 
Salmonella ser. Typhimurium; however, the majority of Typhimurium isolates resistant to these four agents 
showed additional resistance to chloramphenicol (ACSSuT) (Table H2), a pattern which is associated with the 
presence of a chromosomal resistance region called Salmonella Genomic Island 1 (SGI1). In Europe, infections 
with ASSuT-resistant Salmonella ser. I 4,[5],12:i:- have frequently been reported among persons exposed to pigs 
or pork products, and the organism has been isolated from pigs. Investigations are underway to determine the 
source(s) and molecular mechanisms responsible for ASSuT-resistant Salmonella ser. I 4,[5],12:i:- infections in 
the United States. 
 
 
Figure H2.  Percentage of Salmonella ser. I 4,[5],12:i:- isolates with resistance to at least ASSuT*, 2002–2011 
 
* Resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline, and no resistance to chloramphenicol 
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Table H2. Percentage and number of Salmonella ser. I 4,[5],12;i:- and ser. Typhimurium isolates with selected
resistance patterns, 2002–2011
 
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
35 36 36 33 105 73 84 72 78 82
0.0% 0.0% 0.0% 0.0% 1.0% 0.0% 1.2% 1.4% 16.7% 18.3%
0 0 0 0 1 0 1 1 13 15
2.9% 0.0% 2.8% 0.0% 1.9% 1.4% 3.6% 6.9% 1.3% 1.2%
1 0 1 0 2 1 3 5 1 1
394 408 382 438 408 405 397 370 359 323
4.3% 2.7% 2.4% 2.3% 3.2% 3.7% 0.3% 1.6% 3.6% 1.2%
17 11 9 10 13 15 1 6 13 4
21.6% 26.5% 23.6% 22.4% 19.6% 22.7% 23.2% 19.5% 18.7% 19.5%
85 108 90 98 80 92 92 72 67 63
* ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline   
† ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
At least ASSuT* and not resistant to 
chloramphenicol
At least ACSSuT† 
Year
I 4,[5],12:i:- isolates                                       
At least ASSuT* and not resistant to 
chloramphenicol
At least ACSSuT† 
Typhimurium isolates
1
 Hopkins KL, Kirchner M, Guerra B. Granier SA, Lucarelli C, Porrero MC, Jakubczak A, Threlfall EJ, Mevius DJ. Multiresistant Salmonella  
     enterica serovar 4,[5],12:i:- in Europe: a new pandemic strain?. Euro Surveill. 2010; 15(22):pij=19580. Available online:  
     http://www.eurosurveillance.org/images/dynamic/EE/V15N22/art19580.pdf  
 
2
 Lucarelli C, Dionisi AM, Filetici E, Owczarek S, Luzzi I, Villa L. Nucleotide sequence of the chromosomal region conferring multidrug  
    resistance (R-type ASSuT) in Salmonella Typhimurium and monophasic Salmonella Typhimurium strains. JAC 2012;67(1):pp111-4.  
    Available online: http://jac.oxfordjournals.org/content/67/1/111.full.pdf+html  
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Surveillance and Laboratory Testing Methods 
 
Surveillance Sites and Isolate Submissions  
 
In 2011, NARMS conducted nationwide surveillance among approximately 312 million persons (2011 estimates 
published in the 2012 U.S. Census Bureau report). Public health laboratories systematically selected every 20
th
 
non-typhoidal Salmonella, Shigella, and Escherichia coli O157 isolate and every Salmonella ser. Typhi, 
Salmonella ser. Paratyphi A, and Salmonella ser. Paratyphi C isolate received at their laboratories and forwarded 
these isolates to CDC for antimicrobial susceptibility testing. Salmonella ser. Paratyphi B was included in the 
every 20
th
 sampling for non-typhoidal Salmonella because available laboratory methods do not always allow for 
consistent distinction between serotype Paratyphi B (which typically causes typhoidal illness) and serotype 
Paratyphi B var. L(+) tartrate+ (which does not typically cause typhoidal illness). Because the number of serotype 
Paratyphi B (tartrate negative) and serotype Paratyphi C isolates is small, this report includes susceptibility results 
only for serotype Paratyphi A. Beginning in 2009, NARMS also performed susceptibility testing on isolates of 
Vibrio species other than V. cholerae submitted by the NARMS participating public health laboratories. 
Participants were asked to forward every isolate of Vibrio species other than V. cholerae that they received to 
CDC for antimicrobial susceptibility testing by NARMS and confirmation by CDC’s National Enteric Reference 
Laboratory.   
 
Since 2005, public health laboratories of the 10 state health departments that participate in CDC’s Foodborne 
Diseases Active Surveillance Network (FoodNet) have forwarded a sample of Campylobacter isolates received to 
CDC for susceptibility testing. The FoodNet sites, representing approximately 48 million persons (2011 estimates 
published in 2012 U.S. Census Bureau report), include Connecticut, Georgia, Maryland, Minnesota, New Mexico, 
Oregon, Tennessee, and selected counties in California, Colorado, and New York. Depending on the burden of 
Campylobacter in each FoodNet site, one of the following four methods was used to obtain and test a sample of 
Campylobacter isolates: all isolates received by Oregon and Tennessee; every other isolate from California, 
Colorado, Connecticut, Georgia, Maryland, and New York; every third isolate from New Mexico; and every fifth 
isolate from Minnesota.  Isolates received from 2005 to 2009 had the same methods except all isolates were sent 
from Georgia, Maryland, and New Mexico. From 1997 to 2004, one Campylobacter isolate was submitted each 
week from participating FoodNet sites.  
  
 
18 
Table 1. Population size and number of isolates received and tested, NARMS, 2011
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Alabama 4,803,689 (1.5) 55 (2.3) 4 (0.8) 9 (3.1) 0 (0) 0 (0)
Alaska 723,860 (0.2) 4 (0.2) 0 (0) 1 (0.3) 1 (0.6) 0 (0)
Arizona 6,467,315 (2.1) 46 (2.0) 1 (0.2) 13 (4.4) 2 (1.2) 6 (1.5)
Arkansas 2,938,582 (0.9) 35 (1.5) 1 (0.2) 1 (0.3) 0 (0) 0 (0)
California§ 27,794,877 (8.9) 161 (6.9) 81 (15.2) 1 (0.3) 3 (1.9) 146 (9.9) 0 (0)
Colorado 5,116,302 (1.6) 27 (1.2) 7 (1.3) 4 (1.4) 3 (1.9) 37 (2.5) 6 (1.5)
Connecticut 3,586,717 (1.2) 28 (1.2) 5 (0.9) 1 (0.3) 3 (1.9) 168 (11.4) 11 (2.8)
Delaw are 908,137 (0.3) 9 (0.4) 6 (1.1) 0 (0) 0 (0) 3 (0.8)
District of Columbia 619,020 (0.2) 8 (0.3) 0 (0) 0 (0) 0 (0) 0 (0)
Florida 19,082,262 (6.1) 68 (2.9) 15 (2.8) 0 (0) 1 (0.6) 93 (23.3)
Georgia 9,812,460 (3.1) 147 (6.3) 15 (2.8) 30 (10.2) 16 (9.9) 273 (18.5) 17 (4.3)
Haw aii 1,378,129 (0.4) 18 (0.8) 2 (0.4) 6 (2.0) 1 (0.6) 16 (4.0)
Houston, Texas¶ 2,145,146 (0.7) 52 (2.2) 11 (2.1) 7 (2.4) 1 (0.6) 5 (1.3)
Idaho 1,583,744 (0.5) 6 (0.3) 0 (0) 1 (0.3) 1 (0.6) 0 (0)
Illinois 12,859,752 (4.1) 86 (3.7) 44 (8.3) 13 (4.4) 8 (4.9) 1 (0.3)
Indiana 6,516,353 (2.1) 32 (1.4) 11 (2.1) 3 (1.0) 3 (1.9) 0 (0)
Iow a 3,064,097 (1.0) 20 (0.9) 7 (1.3) 0 (0) 5 (3.1) 0 (0)
Kansas 2,870,386 (0.9) 17 (0.7) 1 (0.2) 2 (0.7) 2 (1.2) 0 (0)
Kentucky 4,366,814 (1.4) 27 (1.2) 0 (0) 0 (0) 0 (0) 0 (0)
Los Angeles** 9,889,056 (3.2) 56 (2.4) 21 (3.9) 3 (1.0) 1 (0.6) 0 (0)
Louisiana 4,574,766 (1.5) 57 (2.4) 1 (0.2) 13 (4.4) 0 (0) 30 (7.5)
Maine 1,328,544 (0.4) 1 (< 0.1) 0 (0) 0 (0) 1 (0.6) 1 (0.3)
Maryland 5,839,572 (1.9) 57 (2.4) 21 (3.9) 5 (1.7) 2 (1.2) 183 (12.4) 19 (4.8)
Massachusetts 6,607,003 (2.1) 51 (2.2) 30 (5.6) 9 (3.1) 3 (1.9) 24 (6.0)
Michigan 9,876,801 (3.2) 37 (1.6) 6 (1.1) 5 (1.7) 0 (0) 2 (0.5)
Minnesota 5,347,299 (1.7) 35 (1.5) 6 (1.1) 5 (1.7) 7 (4.3) 180 (12.2) 7 (1.8)
Mississippi 2,977,457 (1.0) 60 (2.6) 1 (0.2) 10 (3.4) 2 (1.2) 10 (2.5)
Missouri 6,008,984 (1.9) 60 (2.6) 3 (0.6) 13 (4.4) 10 (6.2) 1 (0.3)
Montana 997,667 (0.3) 5 (0.2) 1 (0.2) 5 (1.7) 3 (1.9) 0 (0)
Nebraska 1,842,234 (0.6) 12 (0.5) 1 (0.2) 5 (1.7) 4 (2.5) 0 (0)
Nevada 2,720,028 (0.9) 8 (0.3) 6 (1.1) 2 (0.7) 1 (0.6) 1 (0.3)
New  Hampshire 1,317,807 (0.4) 16 (0.7) 0 (0) 1 (0.3) 0 (0) 0 (0)
New  Jersey 8,834,773 (2.8) 34 (1.5) 49 (9.2) 8 (2.7) 5 (3.1) 0 (0)
New  Mexico 2,078,674 (0.7) 18 (0.8) 1 (0.2) 6 (2.0) 0 (0) 87 (5.9) 0 (0)
New  York†† 11,256,706 (3.6) 73 (3.1) 22 (4.1) 6 (2.0) 6 (3.7) 205 (13.9) 29 (7.3)
New  York City‡‡ 8,244,910 (2.6) 68 (2.9) 45 (8.4) 23 (7.8) 3 (1.9) 13 (3.3)
North Carolina 9,651,103 (3.1) 115 (4.9) 10 (1.9) 3 (1.0) 3 (1.9) 1 (0.3)
North Dakota 684,740 (0.2) 3 (0.1) 0 (0) 1 (0.3) 1 (0.6) 0 (0)
Ohio 11,541,007 (3.7) 64 (2.7) 6 (1.1) 6 (2.0) 6 (3.7) 1 (0.3)
Oklahoma 3,784,163 (1.2) 0 (0) 2 (0.4) 1 (0.3) 1 (0.6) 0 (0)
Oregon 3,868,229 (1.2) 20 (0.9) 5 (0.9) 3 (1.0) 4 (2.5) 160 (10.8) 6 (1.5)
Pennsylvania 12,743,948 (4.1) 84 (3.6) 24 (4.5) 5 (1.7) 4 (2.5) 0 (0)
Rhode Island 1,050,646 (0.3) 9 (0.4) 0 (0) 0 (0) 0 (0) 2 (0.5)
South Carolina 4,673,348 (1.5) 75 (3.2) 3 (0.6) 4 (1.4) 2 (1.2) 10 (2.5)
South Dakota 823,593 (0.3) 9 (0.4) 0 (0) 1 (0.3) 3 (1.9) 0 (0)
Tennessee 6,399,787 (2.1) 54 (2.3) 1 (0.2) 10 (3.4) 4 (2.5) 39 (2.6) 5 (1.3)
Texas§§ 23,486,632 (7.5) 245 (10.5) 32 (6.0) 28 (9.6) 5 (3.1) 36 (9.0)
Utah 2,814,347 (0.9) 11 (0.5) 1 (0.2) 3 (1.0) 2 (1.2) 0 (0)
Vermont 626,592 (0.2) 6 (0.3) 0 (0) 1 (0.3) 1 (0.6) 0 (0)
Virginia 8,104,384 (2.6) 39 (1.7) 7 (1.3) 1 (0.3) 3 (1.9) 6 (1.5)
Washington 6,823,267 (2.2) 35 (1.5) 13 (2.4) 6 (2.0) 8 (4.9) 33 (8.3)
West Virginia 1,854,908 (0.6) 35 (1.5) 0 (0) 4 (1.4) 3 (1.9) 0 (0)
Wisconsin 5,709,843 (1.8) 39 (1.7) 4 (0.8) 3 (1.0) 11 (6.8) 4 (1.0)
Wyoming 567,356 (0.2) 7 (0.3) 0 (0) 2 (0.7) 3 (1.9) 1 (0.3)
Total 311,587,816 (100) 2344 (100) 533 (100) 293 (100) 162 (100) 1478 (100) 400 (100)
*    2011 state est imates published in 2012 U.S. Census Bureau populat ion est imates; county and city est imates published in 2011 populat ion est imates
†   Typhoidal Salmonella  includes Typhi, Paratyphi A, Paratyphi B (isolates negat ive for tartrate fermentat ion), and Paratyphi C 
§   Excluding Los Angeles County
¶   Houston City
**   Los Angeles County
†† Excluding New York City
‡‡ Five burroughs of New York City (Bronx, Brooklyn, M anhattan, Queens, Staten Island)
§§ Excluding Houston, Texas
‡  Campylobacter  isolates are submitted only from FoodNet sites which include Connect icut, Georgia, M aryland, M innesota, New M exico, Oregon, Tennessee, and selected count ies in California, Colorado, and New 
     York.  Of the clinical laboratories in each site that perform on-site test ing for Campylobacter  (range,18 to 94 per site in 2011), the number submitt ing isolates to the state public health laboratory ranged from one to all.
Campylobacter
‡ Vibrio
State/Site
Non-typhoidal
Salmonella
Typhoidal
† 
Salmonella 
Shigella E. coli  O157Population Size
*
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Testing of Salmonella, Shigella, and Escherichia coli O157  
 
Antimicrobial Susceptibility Testing 
 
Salmonella, Shigella, and E. coli O157 isolates were tested using broth microdilution (Sensititre®, Trek 
Diagnostics, part of Thermo Fisher Scientific, Cleveland, OH) according to manufacturer’s instructions to 
determine the MICs for each of 15  antimicrobial agents:  ampicillin, amoxicillin-clavulanic acid, azithromycin, 
cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, 
streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole (Table 2). Before 2004, 
sulfamethoxazole was used instead of sulfisoxazole to represent the sulfonamides. Interpretive criteria defined by 
CLSI were used when available. In 2011, azithromycin replaced amikacin on the panel of drugs being tested for  
Salmonella, Shigella, and E. coli O157, so only historical susceptibility data are provided for amikacin. 
 
In January 2010, CLSI published revised interpretive criteria for ceftriaxone and Enterobacteriaceae; the revised 
resistance breakpoint for ceftriaxone is MIC ≥4 μg/mL. Since the 2009 report, NARMS has applied the revised 
CLSI breakpoint for ceftriaxone resistance to data from all years. In January 2012, CLSI published revised 
ciprofloxacin breakpoints for invasive Salmonella infections. For those infections, ciprofloxacin susceptibility is 
defined as ≤0.06 µg/mL; the intermediate category is defined as 0.12 to 0.5 µg/mL; and resistance is defined as 
≥1 µg/mL. For public health surveillance purposes, the new breakpoints were applied to all Salmonella isolates 
because all serotypes have the potential to cause invasive infection. 
 
Repeat testing of isolates was done based on criteria in Appendix B 
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Table 2.  Antimicrobial agents used for susceptibility testing for Salmonella, Shigella, and Escherichia 
coli O157 isolates, NARMS, 1996–2011 
CLSI Class Antimicrobial Agent 
Antimicrobial Agent 
Concentration Range 
(g/mL) 
MIC Interpretive Standard (µg/mL) 
Susceptible Intermediate* Resistant 
Aminoglycosides 
Amikacin
†
 0.5–64 ≤16 32 ≥64 
Gentamicin 0.25–16 ≤4 8 ≥16 
Kanamycin 8–64 ≤16 32 ≥64 
Streptomycin
‡
 32–64 ≤32 N/A ≥64 
β–lactam / β–lactamase 
inhibitor combinations 
Amoxicillin-clavulanic acid 1/0.5–32/16 ≤8/4 16/8 ≥32/16 
Piperacillin-tazobactam
§
 0.5–128 ≤16 32–64 ≥128 
Cephems 
Cefepime
§
 0.06–32 ≤8 16 ≥32 
Cefotaxime
§
 0.06–128 ≤1 2 ≥4 
Cefoxitin 0.5–32 ≤8 16 ≥32 
Ceftazidime
§
 0.06–128 ≤4 8 ≥16 
Ceftiofur 0.12–8 ≤2 4 ≥8 
Ceftriaxone
¶
 0.25–64 ≤1 2 ≥4 
Cephalothin** 2–32 ≤8 16 ≥32 
Folate pathway 
inhibitors 
Sulfamethoxazole
††
 16–512 ≤256 N/A ≥512 
Sulfisoxazole 16–256 ≤256 N/A ≥512 
Trimethoprim- 
sulfamethoxazole 
0.12/2.38–4/76 ≤2/38 N/A ≥4/76 
Macrolides Azithromycin
‡‡
 0.12-16 ≤16 N/A ≥32 
Monobactams Aztreonam
§
 0.06–32 ≤4 8 ≥16 
Penems Imipenem
§
 0.06–16 ≤1 2 ≥4 
Penicillins Ampicillin 1–32 ≤8 16 ≥32 
Phenicols Chloramphenicol 2–32 ≤8 16 ≥32 
Quinolones 
Ciprofloxacin
§§
 0.015–4 ≤1 2 ≥4 
Nalidixic acid 0.5–32 ≤16 N/A ≥32 
Tetracyclines Tetracycline 4–32 ≤4 8 ≥16 
 
   *          N/A indicates that no MIC range of intermediate susceptibility exists  
   †      Amikacin was tested from 1997 to 2010 for Salmonella, Shigella, and E. coli O157 
   ‡      No CLSI breakpoints; resistance breakpoint used in NARMS is ≥64 µg/mL 
   §      Broad-spectrum β-lactam antimicrobial agent only tested for 2011 non-typhoidal Salmonella isolates displaying ceftriaxone       
          and/or  ceftiofur resistance 
   ¶     CLSI updated the ceftriaxone interpretive standards in January, 2010.  NARMS  Human Isolate reports for 1996 through        
        2008 used susceptible ≤8 µg/mL, intermediate 16-32 µg/mL, and resistant ≥64 µg/mL. 
   **    Cephalothin was tested from 1996 to 2003 for Salmonella, Shigella, and E. coli O157 
   †† Sulfamethoxazole, which was tested during 1996–2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004 
   ‡‡ CLSI breakpoints are not established for azithromycin. The azithromycin breakpoints used in this report are NARMS- 
         established breakpoints for resistance monitoring and should not be used to predict clinical efficacy. 
   §§ CLSI breakpoints for invasive Salmonella infections were updated, effective January 2012. For Salmonella,  
        ciprofloxacin susceptibility is defined as ≤0.06 µg/mL; the intermediate category is defined as 0.12 to 0.5 µg/mL;    
        and resistance is defined as ≥1 µg/mL.   
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Additional Testing of Salmonella Strains 
 
β-lactam Panel Testing 
Isolates displaying resistance to either ceftriaxone (MIC ≥4 μg/mL) or ceftiofur (MIC ≥8 μg/mL) on the Trek 
Sensititre® gram-negative panel (described above) were subsequently tested using broth microdilution on a 
Sensititre® β-lactam panel (Trek Diagnostics, part of Thermo Fisher Scientific, Cleveland, OH) according to 
manufacturer’s instruction. The panel contained additional broad-spectrum β-lactam drugs: aztreonam, cefepime, 
cefotaxime, ceftazidime, imipenem, and piperacillin-tazobactam (Table 2). Briefly, a suspension of each isolate 
was made in water to a McFarland standard equivalency of 0.5, 10uL of this suspension was then used to 
inoculate a 10mL tube of Muller-Hinton broth, 50uL of this inoculated broth was dosed into each well of the 96-
well β-lactam panel plate, and results were read manually after 18-20 hours of incubation at 35°C. Quality control 
isolates for this testing were E. coli ATCC 25922, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, and 
S. aureus ATCC 29213.  
 
Cephalosporin Retesting of Isolates from 1996-1998 
 
Salmonella isolates tested in NARMS during 1996 to 1998 had conflicting cephalosporin susceptibility results. In 
particular, some isolates previously reported in NARMS as ceftiofur-resistant exhibited a low ceftriaxone MIC and 
some did not exhibit an elevated MIC to other β-lactams. Because these findings suggested that some previously 
reported results were inaccurate, we retested using the 2003 NARMS Sensititre
®
 plate, isolates of Salmonella 
tested in NARMS during 1996 to 1998 that exhibited an MIC ≥2 μg/mL to ceftiofur or ceftriaxone. The retest 
results have been included in the NARMS annual reports since 2003. 
 
Serotype Confirmation/Categorization 
 
Salmonella serotype reported by the submitting laboratory was used for reporting with few exceptions. Serotype 
was confirmed by CDC for isolates that underwent subsequent molecular analysis for publication. Because of 
challenges associated with interpretation of tartrate fermentation assays, ability to ferment tartrate was confirmed 
for isolates reported as Salmonella ser. Paratyphi B by the submitting laboratory (serotype Paratyphi B is by 
definition unable to ferment L(+) tartrate). To distinguish Salmonella serotypes Paratyphi B and Paratyphi B var. 
L(+) tartrate+ (formerly serotype Java), CDC performed Jordan’s tartrate test or Kauffmann’s tartrate test or both 
tests on all Salmonella ser. Paratyphi B isolates from 1996 to 2011 for which the tartrate result was not reported 
or was reported to be negative. Isolates negative for tartrate fermentation by both assays were categorized as 
serotype Paratyphi B. Isolates that were positive for tartrate fermentation by either assay were categorized as 
serotype Paratyphi B var. L(+) tartrate+. CDC did not confirm other biochemical reactions or somatic and flagellar 
antigens. 
 
Because of increased submissions of Salmonella ser. I 4,[5],12:i:- noted in previous years, and recognition of the 
possibility that this serotype may have been underreported in previous years, isolates reported as serogroup B 
and tested in NARMS during 1996 to 2011 were reviewed for additional information; isolates that could be clearly 
identified as serogroup B, first-phase flagellar antigen “i” second phase flagellar antigen absent were categorized 
in this report as Salmonella ser. I 4,[5],12:i:-. 
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Testing of Campylobacter 
 
Changes in Sampling Scheme in 2010 
 
The number of isolates received from Georgia, Maryland, and New Mexico increased over time. To avoid 
oversampling from these sites, instead of testing all isolates that had been received for 2010, the scheme for 
testing isolates was changed to every other isolate from Georgia and Maryland and every third from New Mexico. 
 
Changes in Testing Methods in 2005 
 
Starting in 2005, there were four changes in the methodology used for Campylobacter. First, a surveillance 
scheme for selecting a more representative sample of Campylobacter isolates for submission by FoodNet sites 
was implemented. State public health laboratories within FoodNet sites receive Campylobacter isolates from 
reference and clinical laboratories within their state. In 2005, FoodNet sites changed from submitting the first 
isolate received each week to submitting every isolate (Georgia, Maryland, New Mexico, Oregon, and 
Tennessee), every other isolate (California, Colorado, Connecticut, and New York), or every fifth isolate received 
(Minnesota). Of the clinical laboratories in each site that perform on-site testing for Campylobacter (range,18 to 94 
per site in 2011), the number submitting isolates to the state public health laboratory ranged from one to all. 
Second, the method of species identification was updated to parallel what is used by the CDC National 
Campylobacter Laboratory. Third, the susceptibility testing method changed from Etest® (AB bioMerieux, Solna, 
Sweden) to broth microdilution. Fourth, there were changes in the antimicrobial agents tested. Florfenicol 
replaced chloramphenicol as the phenicol class representative drug, and telithromycin was added to the panel of 
agents tested. These changes in methods began in 2005 and continue through this report except for noted 
changes to submissions from Georgia, Maryland, and New Mexico beginning in 2010. 
 
Identification/Speciation and Antimicrobial Susceptibility Testing 
 
All 2011 isolates were confirmed as Campylobacter using a genus polymerase chain reaction (PCR) (Linton et al. 
1996) and run on a multiplex PCR assay (Vandamme et al. 1997) to identify C. jejuni and C. coli. Isolates needing 
further characterization were tested using a short set of biochemical and other species-specific PCR assays, if 
necessary. From 2005 to 2010, isolates were confirmed as Campylobacter by determination of typical morphology 
and motility using dark-field microscopy and a positive oxidase test reaction. Identification of C. jejuni was 
performed using the hippurate hydrolysis test. Hippurate-positive isolates were identified as C. jejuni. Hippurate-
negative isolates were further characterized with PCR assays with specific targets for C. jejuni (mapA or hipO 
gene), C. coli-specific ceuE gene (Linton et al. 1997, Gonzales et al. 1997, Pruckler et al. 2006), or other species-
specific primers. In 2010, all jejuni and suspected coli isolates were also confirmed through a multiplex PCR 
(Vandamme et al. 1997). Additionally the ceuE PCR was not used in 2010. From 2003 to 2004, putative 
Campylobacter isolates were identified as C. jejuni or C. coli using BAX® System PCR Assay according to the 
manufacturer's instructions (DuPont Qualicon, Wilmington, DE). Isolates not identified as C. jejuni or C. coli were 
further characterized by other PCR assays (Linton et al. 1996) or were characterized by the CDC National 
Campylobacter Reference Laboratory. From 1997 to 2002, methodology similar to that used from 2005 to 2009 
was used. 
 
The methods for susceptibility testing of Campylobacter and criteria for interpreting the results have changed 
during the course of NARMS surveillance. Beginning in 2005, broth microdilution using the Sensititre® system 
(Trek Diagnostics, part of Thermo Fisher Scientific, Cleveland, OH) was performed according to manufacturer’s 
instructions to determine the MICs for nine antimicrobial agents: azithromycin, ciprofloxacin, clindamycin, 
erythromycin, florfenicol, gentamicin, nalidixic acid, telithromycin, and tetracycline (Table 3). CLSI 
recommendations for quality control were followed. From 1997 to 2004, Etest® (AB bioMerieux, Solna, Sweden) 
was used for susceptibility testing of Campylobacter isolates. Campylobacter-specific CLSI interpretive criteria 
were used for erythromycin, ciprofloxacin, and tetracycline beginning with the 2004 NARMS annual report.  
NARMS breakpoints were used for agents for which CLSI breakpoints were not available. Beginning in 2004, 
NARMS breakpoints were established based on the MIC distributions of NARMS isolates and the presence of 
known resistance genes or mutations. In pre-2004 annual reports, NARMS breakpoints used had been based on 
those available for other organisms. Establishment of breakpoints based on MIC distributions resulted in higher 
MIC breakpoints for azithromycin and erythromycin resistance compared with those reported in pre-2004 annual 
reports. The breakpoints listed in Table 3 have been applied to MIC data collected for all years so that resistance 
prevalence is comparable over time. Repeat testing of isolates was done based on criteria in Appendix B. 
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Table 3.  Antimicrobial agents used for susceptibility testing of Campylobacter isolates, NARMS,       
1997–2011 
CLSI Class 
Antimicrobial 
Agent 
Antimicrobial Agent 
Concentration Range (µg/mL) 
MIC Interpretive Standard (µg/mL) 
Susceptible Intermediate Resistant 
Aminoglycosides Gentamicin 
0.12–32 
0.016–256* 
≤2 4 ≥8 
Ketolides Telithromycin
†
 0.015–8 ≤4 8 ≥16 
Lincosamides Clindamycin 
0.03–16 
0.016–256* 
≤2 4 ≥8 
Macrolides 
Azithromycin 
0.015–64 
0.016–256* 
≤2 4 ≥8 
Erythromycin 
0.03–64 
0.016–256* 
≤8 16 ≥32 
Phenicols 
Chloramphenicol
‡
 0.016–256* ≤8 16 ≥32 
Florfenicol
§
 0.03–64 ≤4 N/A N/A 
Quinolones 
Ciprofloxacin 
0.015–64 
0.002–32* 
≤1 2 ≥4 
Nalidixic acid 
4–64 
0.016–256* 
≤16 32 ≥64 
Tetracyclines Tetracycline 
0.06–64 
0.016–256* 
≤4 8 ≥16 
N/A indicates that no MIC range of either intermediate or resistant susceptibility exists 
*  Etest dilution range used from 1997–2004 
† Telithromycin added to NARMS panel in 2005 
‡ Chloramphenicol, tested from 1997–2004, was replaced by florfenicol in 2005 
§ Only a susceptible breakpoint (≤4 µg/mL) has been established by CLSI.  In this report isolates with a MIC ≥8 µg/mL are  
   categorized as resistant. 
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Testing of Vibrio species other than V. cholerae 
 
NARMS participating public health laboratories were asked to forward every isolate of Vibrio species other than V. 
cholerae they received to CDC for antimicrobial susceptibility testing by the NARMS laboratory and confirmation 
of identity by CDC’s National Enteric Reference Laboratory. Minimum inhibitory concentrations were determined 
by Etest® (AB bioMerieux, Solna, Sweden) according to manufacturer’s instructions for nine antimicrobial agents: 
ampicillin, cephalothin, chloramphenicol, ciprofloxacin, kanamycin, nalidixic acid, streptomycin, tetracycline, and 
trimethoprim-sulfamethoxazole (Table 4). CLSI breakpoints specific for Vibrio species other than V. cholerae were 
available for ampicillin, ciprofloxacin, tetracycline, and trimethoprim-sulfamethoxazole. Frequency of isolates 
susceptible, intermediate, and resistant to those agents is shown in this report (Table 54). MIC distributions are 
shown for all agents tested.   
 
 
Table 4. Antimicrobial agents used for susceptibility testing of Vibrio species other than V. cholerae 
isolates, NARMS, 2009–2011 
CLSI Class 
Antimicrobial 
Agent 
Antimicrobial Agent 
Concentration Range 
(g/mL) 
MIC Interpretive Standard (µg/mL) 
Susceptible Intermediate* Resistant 
Aminoglycosides 
Kanamycin
†
 0.016-256    
Streptomycin
†
 0.064-1024    
Cephems Cephalothin
†
 0.016-256    
Folate pathway inhibitors 
Trimethoprim- 
sulfamethoxazole 
0.002-32 ≤2/38 N/A ≥4/76 
Penicillins Ampicillin 0.016-256 ≤8 16 ≥32 
Phenicols Chloramphenicol
†
 0.016-256    
Quinolones 
Ciprofloxacin 0.002-32 ≤1 2 ≥4 
Nalidixic acid
†
 0.016-256    
Tetracyclines Tetracycline 0.016-256 ≤4 8 ≥16 
 
*    N/A indicates that no MIC range of intermediate susceptibility exists 
† No CLSI or NARMS breakpoints established 
 
 
Testing of Representative Bacteria from Outbreaks 
 
To aid in outbreak investigations and food source attribution, CDC NARMS performs antimicrobial susceptibility 
testing on isolates from outbreaks submitted by state and local health departments to determine their resistance 
patterns. In the 2010 NARMS Annual Report, CDC published an analysis of antimicrobial susceptibility data from 
non-typhoidal Salmonella outbreaks in the United States from 2004 through 2008. CDC is currently updating and 
reanalyzing these data. A summary report of updated non-typhoidal Salmonella outbreak data will be published in 
the future. 
 
 
Data Analysis 
 
For all pathogens, isolates were categorized as resistant, intermediate (if applicable), or susceptible. Analysis was 
restricted to the first isolate received (per serotype for Salmonella, per species for Shigella and Campylobacter) 
per patient in the calendar year. If two or more Salmonella ser. Typhi isolates were received for the same patient, 
the first blood isolate collected was included in the analysis; if no blood isolates were submitted, the first isolate 
collected was included in analysis. The 95% confidence intervals (CIs) for the percentage resistant, which were 
calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method, are included in the 
MIC distribution tables.  
 
In the analysis of antimicrobial class resistance among Salmonella, Shigella, and E. coli O157, nine CLSI 
classes (Table 2) were represented by the following 15 agents: amoxicillin-clavulanic acid, ampicillin, 
azithromycin, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic 
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acid, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. Isolates 
that were not resistant to any of these 15 agents were considered to have no resistance detected. In the 
analysis of antimicrobial class resistance among Campylobacter, six CLSI classes were represented by 
azithromycin, ciprofloxacin, chloramphenicol/florfenicol, clindamycin, erythromycin, gentamicin, nalidixic acid, 
and tetracycline (Table 3). Campylobacter isolates that were not resistant to any of these agents were 
considered to have no resistance detected. 
 
Logistic regression was used to compare the prevalence of antimicrobial resistance among Salmonella, Shigella, 
and Campylobacter isolates tested in 2011 with the average prevalence of resistance in the first five years that 
NARMS surveillance was nationwide (2003–2007). The prevalence of resistance was defined as the percentage 
of resistant isolates among total isolates tested. Changes in the prevalence of resistance do not provide 
information about changes in the incidence of resistant infections. The incidence and relative changes in the 
incidence of Salmonella, Shigella, and Campylobacter infections are reported annually from surveillance in 
FoodNet sites (CDC, 2012). Comparisons were made for the following: 
 
 Non-typhoidal Salmonella: resistance to nalidixic acid, ceftriaxone, one or more CLSI classes, three or more 
CLSI classes 
 Salmonella of particular serotypes 
o Salmonella ser. Enteritidis: resistance to nalidixic acid 
o Salmonella ser. Typhimurium: resistance to at least ACSSuT (ampicillin, chloramphenicol, 
streptomycin, sulfonamide, and tetracycline) 
o Salmonella ser. Newport: resistance to at least ACSSuTAuCx (ACSSuT, amoxicillin-clavulanic acid, 
and ceftriaxone) 
o Salmonella ser. Typhi: resistance to nalidixic acid 
 Shigella: resistance to nalidixic acid 
 Campylobacter species: resistance to ciprofloxacin 
o Campylobacter jejuni: resistance to ciprofloxacin 
 
To account for site-to-site variation in the prevalence of antimicrobial resistance, we included main effects 
adjustments for site in the analysis. The final regression models for Salmonella and Shigella adjusted for the 
submitting site using the nine geographic regions described by the U.S. Census Bureau: East North Central, East 
South Central, Mid-Atlantic, Mountain, New England, Pacific, South Atlantic, West North Central, and West South 
Central. For Campylobacter, the final regression models adjusted for the submitting FoodNet site. Odds ratios 
(ORs) and 95% confidence intervals (CIs) were calculated using unconditional maximum likelihood estimation. 
The adequacy of model fit was assessed in several ways (Fleiss et al., 2004; Kleinbaum et al., 2008). The 
significance of the main effect of year was assessed using the likelihood ratio test. The likelihood ratio test was 
also used to test for significance of interaction between site and year, although the power of the test to detect a 
single site-specific interaction was low. Having assessed that the main effect of year was significant, we reported 
ORs with 95% CIs (for 2011 compared with 2003-2007) that did not include 1.0 as statistically significant. 
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MIC Distribution Tables and Proportional Figures 
 
An explanation on “how to read a squashtogram” has been provided to assist the reader with the different parts of 
the table (Figure 1). A squashtogram shows the distribution of MICs for antimicrobial agents tested. Proportional 
figures visually display data from squashtograms for an immediate comparative summary of resistance in specific 
pathogens and serotypes. These figures are a categorical visual aid for the interpretation of MIC values. For most 
antimicrobial agents tested, three categories (susceptible, intermediate, and resistant) are used to interpret 
MICs.The proportion representing each category is shown in a horizontal proportional bar chart (Figure 2). 
 
Figure 1.  How to read a squashtogram 
 
 
  
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–0.2] 7.4 70.1 20.8 1.6 0.1
Gentamicin 0.1 2.1 [1.5–2.8] 53.5 41.4 2.8 0.1 0.1 0.9 1.2
Streptomycin N/A 10.4 [9.1–11.7] 89.6 4.4 6.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 4.2 3.3 [2.6–4.1] 84.8 4.9 0.4 2.5 4.2 0.6 2.7
Cephems Ceftiofur 0.0 3.2 [2.6–4.1] 0.3 0.8 27.5 66.7 1.4 0.1 3.1
Ceftriaxone 2.3 0.4 [0.2–0.8] 96.7 0.1 0.5 1.4 0.9 0.3 0.1
Penicillins Ampicillin 0.0 10.1 [8.9–11.5] 81.2 8.3 0.3 0.1 0.1 10.0
Quinolones Ciprofloxacin 0.0 0.1 [0.0–0.3] 92.9 4.4 0.2 1.3 0.8 0.3 0.1
Nalidixic acid N/A 2.2 [1.7–3.0] 0.1 0.2 34.4 61.9 0.9 0.2 2.2
Aminoglycosides Kanamycin < 0.1 2.8 [2.2–3.6] 96.8 0.2 < 0.1 0.2 2.6
Cephems Cefoxitin 0.7 3.0 [2.3–3.7] 0.2 8.8 70.2 15.8 1.3 0.7 0.9 2.1
Folate pathway inhibitors Sulfisoxazole N/A 12.3 [11.0–13.8] 19.0 53.1 15.0 0.5 0.1 12.3
Trimethoprim-sulfamethoxazole N/A 1.6 [1.1–2.2] 79.7 18.3 0.2 0.2 0.1 1.5
Phenicols Chloramphenicol 0.7 7.3 [6.2–8.5] 0.8 41.7 49.5 0.7 0.4 6.9
Tetracyclines Tetracycline 0.1 14.5 [13.0–16.0] 85.4 0.1 0.9 4.2 9.4
CLSI† Antimicrobial Class Antimicrobial Agent
II
Percent of all isolates with MIC (µg/mL)**% of isolates
Rank *
I
Critically important 
antimicrobial agents
Highly important 
antimicrobial agents
Percent with
Intermediate result
Percent 
resistant
95% confidence interval 
for percent resistant
Sum of percents = 
% susceptible
Sum of percents = 
% intermediate
Sum of percents = 
% resistant
Single line is upper limit of 
susceptibility / lower limit of 
intermediate result
Double line is upper limit of 
intermediate result / lower limit 
of full resistance 
MIC value
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Figure 2.  Proportional chart, a categorical graph of a squashtogram 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin <0.1 1.7 [1.2 - 2.3] 8.3 76.4 13.1 0.5 <0.1 0.2 1.5
Kanamycin <0.1 1.7 [1.2 - 2.3] 98.2 0.1 <0.1 <0.1 1.6
Streptomycin N/A 9.8 [8.6 - 11.1] 90.2 2.3 7.5
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 2.0 2.6 [2.0 - 3.3] 89.2 1.7 0.6 3.9 2.0 0.8 1.8
Cephems Ceftiofur <0.1 2.5 [1.9 - 3.2] 0.3 0.8 37.7 57.7 1.0 <0.1 0.2 2.3
Ceftriaxone <0.1 2.5 [1.9 - 3.2] 97.5 <0.1 0.1 0.3 1.0 0.8 0.3 0.1
Macrolide Azithromycin N/A 0.2 [0.1 - 0.5] 0.2 0.4 11.2 80.4 7.3 0.2 0.2
Penicillins Ampicillin 0.1 9.1 [8.0 - 10.3] 86.9 3.5 0.3 0.1 0.1 0.2 8.9
Quinolones Ciprofloxacin 2.8 0.2 [0.0 - 0.4] 91.9 4.9 0.2 1.0 0.9 0.9 0.1 0.1
Nalidixic acid N/A 2.4 [1.8 - 3.1] 0.2 0.6 47.4 48.1 0.9 0.4 0.1 2.3
Cephems Cefoxitin 0.2 2.6 [2.0 - 3.3] 0.4 31.1 53.7 10.7 1.3 0.2 1.1 1.5
Folate pathway inhibitors Sulfisoxazole N/A 8.6 [7.5 - 9.8] 5.9 46.1 37.8 1.5 8.6
Trimethoprim-sulfamethoxazole N/A 1.2 [0.8 - 1.7] 96.8 1.7 0.2 <0.1 <0.1 1.2
Phenicols Chloramphenicol 0.6 4.4 [3.6 - 5.3] 0.9 51.0 43.1 0.6 0.1 4.3
Tetracyclines Tetracycline 0.2 10.5 [9.2 - 11.8] 89.4 0.2 0.3 1.9 8.2
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
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1.  Non-typhoidal Salmonella 
 
Table 5.  Number of  non-typhoidal Salmonella isolates among the 20 most common serotypes tested by NARMS with the number of resistant isolates 
by class and agent, 2011 
Serotype N (%) 0 1 2–3 4–5 6–7 8–9 GEN KAN STR AMC FOX TIO AXO FIS COT AZI AMP CHL CIP NAL TET
Enteritidis 391 (16.7) 344 37 5 5 0 0 2 1 7 1 1 1 1 8 2 0 20 0 0 28 7
Typhimurium 323 (13.8) 223 7 23 50 20 0 7 13 83 22 22 22 22 88 6 0 83 63 0 1 88
Newport 285 (12.2) 269 3 2 1 9 1 2 1 12 11 11 11 11 13 0 0 11 10 0 1 13
Javiana 170 (7.3) 168 1 1 0 0 0 0 0 0 1 1 1 1 0 0 0 2 0 0 0 0
I 4,[5],12:I:- 82 (3.5) 54 5 6 16 1 0 1 0 20 4 4 3 3 19 1 0 22 2 0 0 21
Heidelberg 70 (3.0) 39 0 28 0 3 0 14 15 26 7 6 6 6 5 1 0 21 3 0 0 24
Montevideo 65 (2.8) 61 1 2 0 1 0 0 0 2 1 1 1 1 2 1 0 1 1 0 1 4
Infantis 63 (2.7) 59 0 2 2 0 0 1 0 3 1 1 1 1 3 1 0 1 1 0 1 3
Muenchen 49 (2.1) 48 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
Braenderup 48 (2.0) 45 1 1 1 0 0 1 0 2 0 0 0 0 2 1 1 1 0 0 0 3
Oranienburg 48 (2.0) 46 0 0 1 1 0 0 0 2 0 0 0 0 2 1 1 2 1 0 1 2
Paratyphi B var. L(+) tartrate+ 42 (1.8) 38 2 1 1 0 0 0 0 2 0 1 0 0 2 0 0 1 1 0 1 1
Saintpaul 36 (1.5) 28 2 5 1 0 0 2 0 2 1 0 1 1 3 0 0 4 1 0 2 4
Agona 30 (1.3) 17 8 2 1 2 0 1 1 12 2 2 2 2 5 0 0 3 1 0 0 6
Poona 25 (1.1) 25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mississippi 22 (0.9) 21 0 0 1 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 0 1
Rubislaw 22 (0.9) 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Thompson 22 (0.9) 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Berta 21 (0.9) 15 2 4 0 0 0 3 0 2 1 1 1 1 2 0 0 4 0 0 0 2
Bareilly 20 (0.9) 18 0 2 0 0 0 0 0 0 0 0 0 0 2 2 0 0 0 0 0 2
Subtotal 1834 (78.2) 1562 70 84 80 37 1 34 32 176 52 51 50 50 157 17 3 177 84 0 36 181
All other serotypes 411 (17.5) 353 17 22 9 9 1 5 5 37 8 8 8 8 28 9 2 20 14 4 7 46
Unknown serotype 54 (2.3) 34 10 2 6 2 0 1 1 10 0 1 0 0 10 1 0 8 4 0 13 9
Partially serotyped 24 (1.0) 22 1 0 1 0 0 0 0 1 0 0 0 0 1 0 0 1 0 0 0 2
Rough/Nonmotile isolates 21 (0.9) 12 3 0 6 0 0 0 1 6 0 0 0 0 6 1 0 7 1 0 1 7
Total 2344 (100) 1983 101 108 102 48 2 40 39 230 60 60 58 58 202 28 5 213 103 4 57 245
*
†
4
3
2
1
9
8
7
6
5
13
17
15
CLSI: Clinical and Laboratory Standards Institute
Antimicrobial agent abbreviations: GEN, gentamicin; KAN, kanamycin; STR, streptomycin; AMC, amoxicillin-clavulanic acid; FOX, cefoxitin; TIO, ceftiofur; AXO, ceftriaxone; FIS, sulfisoxazole; COT, trimethoprim-sulfamethoxazole; AZI, azithromycin; 
AMP, ampicillin; CHL, chloramphenicol; CIP, ciprofloxacin; NAL, nalidixic acid; TET, tetracycline
10
16
14
12
11
20
19
18
Quinolones TetracyclinesCephems
Folate 
pathway 
inhibitors
Penicillins Phenicols
Number of Isolates
Number of CLSI* Antimicrobial 
Classes to which Isolates are 
Resistant
β-lactam/β-
lactamase 
inhibitor 
combinations
Macrolides
Rank
Aminoglycosides
Isolates
Number of Resistant Isolates by CLSI* Antimicrobial Class and Agent
†
 
 
Results 
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Table 6.  Percentage and number of non-typhoidal Salmonella isolates in NARMS with selected resistance 
patterns, by serotype, 2011 
N n (%) n (%) n (%) n (%) n (%) n (%)
Enteritidis 391 0 (0) 0 (0) 0 (0) 28 (49.1) 1 (1.7) 0 (0)
Typhimurium 323 63 (69.2) 2 (22.2) 17 (47.2) 1 (1.8) 22 (37.9) 0 (0)
Newport 285 10 (11.0) 0 (0) 10 (27.8) 1 (1.8) 11 (19.0) 1 (50.0)
Javiana 170 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.7) 0 (0)
I 4,[5],12:i:- 82 1 (1.1) 0 (0) 0 (0) 0 (0) 3 (5.2) 0 (0)
Heidelberg 70 1 (1.1) 1 (11.1) 1 (2.8) 0 (0) 6 (10.3) 0 (0)
Montevideo 65 1 (1.1) 0 (0) 1 (2.8) 1 (1.8) 1 (1.7) 0 (0)
Infantis 63 0 (0) 0 (0) 0 (0) 1 (1.8) 1 (1.7) 0 (0)
Muenchen 49 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Braenderup 48 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Oranienburg 48 1 (1.1) 1 (11.1) 0 (0) 1 (1.8) 0 (0) 0 (0)
Paratyphi B var. L(+) tartrate+ 42 1 (1.1) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
Saintpaul 36 0 (0) 0 (0) 0 (0) 2 (3.5) 1 (1.7) 0 (0)
Agona 30 1 (1.1) 0 (0) 1 (2.8) 0 (0) 2 (3.4) 0 (0)
Poona 25 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Mississippi 22 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Rubislaw 22 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Thompson 22 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Berta 21 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.7) 0 (0)
Bareilly 20 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Panama 16 1 (1.1) 2 (22.2) 0 (0) 0 (0) 0 (0) 0 (0)
Hadar 14 0 (0) 0 (0) 0 (0) 2 (3.5) 0 (0) 0 (0)
Senftenberg 12 0 (0) 0 (0) 0 (0) 1 (1.8) 2 (3.4) 1 (50.0)
Dublin 10 4 (4.4) 0 (0) 4 (11.1) 1 (1.8) 4 (6.9) 0 (0)
Kentucky 4 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
Virchow 4 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
Muenster 3 1 (1.1) 0 (0) 1 (2.8) 0 (0) 1 (1.7) 0 (0)
Reading 3 1 (1.1) 0 (0) 1 (2.8) 0 (0) 1 (1.7) 0 (0)
Choleraesuis 1 0 (0) 1 (11.1) 0 (0) 1 (1.8) 0 (0) 0 (0)
1901 86 (94.5) 7 (77.8) 36 (100) 43 (75.4) 58 (100) 2 (100)
All other serotypes 344 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Unknown serotype 54 4 (4.4) 1 (11.1) 0 (0) 13 (22.8) 0 (0) 0 (0)
Partially serotyped 24 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Rough/Nonmotile isolates 21 1 (1.1) 1 (11.1) 0 (0) 1 (1.8) 0 (0) 0 (0)
2344 91 (100) 9 (100) 36 (100) 57 (100) 58 (100) 2 (100)
*
†
‡
§
¶
Twenty most common serotypes
Additional serotypes
¶
Subtotal
Total
ACSSuT* ACT/S
†
ACSSuTAuCx
‡
Nalidixic Acid Ceftriaxone CxNal
§
12
1
2
3
4
5
6
7
8
9
10
11
19
20
13
14
15
16
17
18
ACSSuT: at least resistant to ampicillin, chloramphenicol, streptomycin, sulfisoxazole, tetracycline
ACT/S: at least resistant to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: at least resistant to ACSSuT, amoxicillin-clavulanic acid, and ceftriaxone
CxNal: at least resistant to ceftriaxone and nalidixic acid
Additional serotypes that displayed resistance to at least one of the selected patterns
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Table 7.  Minimum inhibitory concentrations (MICs) and resistance of non-typhoidal Salmonella isolates 
to antimicrobial agents, 2011 (N=2344) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin <0.1 1.7 [1.2 - 2.3] 8.3 76.4 13.1 0.5 <0.1 0.2 1.5
Kanamycin <0.1 1.7 [1.2 - 2.3] 98.2 0.1 <0.1 <0.1 1.6
Streptomycin N/A 9.8 [8.6 - 11.1] 90.2 2.3 7.5
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 2.0 2.6 [2.0 - 3.3] 89.2 1.7 0.6 3.9 2.0 0.8 1.8
Cephems Ceftiofur <0.1 2.5 [1.9 - 3.2] 0.3 0.8 37.7 57.7 1.0 <0.1 0.2 2.3
Ceftriaxone <0.1 2.5 [1.9 - 3.2] 97.5 <0.1 0.1 0.3 1.0 0.8 0.3 0.1
Macrolide Azithromycin N/A 0.2 [0.1 - 0.5] 0.2 0.4 11.2 80.4 7.3 0.2 0.2
Penicillins Ampicillin 0.1 9.1 [8.0 - 10.3] 86.9 3.5 0.3 0.1 0.1 0.2 8.9
Quinolones Ciprofloxacin 2.8 0.2 [0.0 - 0.4] 91.9 4.9 0.2 1.0 0.9 0.9 0.1 0.1
Nalidixic acid N/A 2.4 [1.8 - 3.1] 0.2 0.6 47.4 48.1 0.9 0.4 0.1 2.3
Cephems Cefoxitin 0.2 2.6 [2.0 - 3.3] 0.4 31.1 53.7 10.7 1.3 0.2 1.1 1.5
Folate pathway inhibitors Sulfisoxazole N/A 8.6 [7.5 - 9.8] 5.9 46.1 37.8 1.5 8.6
Trimethoprim-sulfamethoxazole N/A 1.2 [0.8 - 1.7] 96.8 1.7 0.2 <0.1 <0.1 1.2
Phenicols Chloramphenicol 0.6 4.4 [3.6 - 5.3] 0.9 51.0 43.1 0.6 0.1 4.3
Tetracyclines Tetracycline 0.2 10.5 [9.2 - 11.8] 89.4 0.2 0.3 1.9 8.2
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Figure 3.  Antimicrobial resistance pattern for non-typhoidal Salmonella, 2011 
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Table 8.  Percentage and number of non-typhoidal Salmonella isolates resistant to antimicrobial agents, 
2002–2011 
2002
1998
2003
1855
2004
1782
2005
2036
2006
2171
2007
2145
2008
2384
2009
2193
2010
2449
2011
2344
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
< 0.1% 
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
1.4%
27
1.4%
26
1.3%
24
2.2%
44
2.0%
44
2.1%
45
1.5%
35
1.3%
28
1.0%
24
1.7%
40
Kanamycin
(MIC ≥ 64)
3.8%
76
3.5%
64
2.8%
50
3.4%
70
2.9%
63
2.8%
61
2.1%
50
2.5%
54
2.2%
54
1.7%
39
Streptomycin
(MIC ≥ 64)
13.2%
264
15.0%
279
12.0%
213
11.1%
225
10.7%
233
10.3%
222
10.0%
238
8.9%
196
8.6%
210
9.8%
230
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
5.3%
106
4.6%
86
3.7%
66
3.2%
65
3.7%
81
3.3%
70
3.1%
73
3.4%
75
2.9%
70
2.6%
60
Ceftiofur
(MIC ≥ 8)
4.4%
87
4.5%
83
3.4%
60
2.9%
60
3.6%
79
3.3%
70
3.1%
73
3.4%
75
2.8%
69
2.5%
58
Ceftriaxone
(MIC ≥ 4)
4.4%
87
4.4%
81
3.3%
59
2.9%
59
3.7%
80
3.3%
70
3.1%
73
3.4%
75
2.9%
70
2.5%
58
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.2%
5
Penicillins Ampicillin
(MIC ≥ 32)
13.0%
259
13.6%
253
12.1%
216
11.4%
232
10.9%
237
10.1%
217
9.7%
232
9.8%
216
9.1%
223
9.1%
213
Ciprofloxacin
(MIC ≥ 1)
0.1%
1
0.2%
4
0.3%
5
0.1%
2
0.1%
3
0.1%
2
0.2%
5
0.3%
7
0.2%
6
0.2%
4
Nalidixic Acid
(MIC ≥ 32)
1.6%
32
1.9%
36
2.2%
39
1.9%
38
2.4%
52
2.2%
48
2.1%
49
1.8%
39
2.0%
48
2.4%
57
Cefoxitin
(MIC ≥ 32)
4.3%
86
4.3%
79
3.4%
61
3.0%
62
3.5%
77
2.9%
63
3.0%
72
3.2%
71
2.6%
63
2.6%
60
Cephalothin
(MIC ≥ 32)
5.1%
101
5.3%
99
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
12.9%
258
15.1%
280
13.3%
237
12.6%
256
12.1%
263
12.3%
264
10.1%
240
9.9%
217
9.0%
221
8.6%
202
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
1.4%
28
1.9%
36
1.7%
31
1.7%
34
1.7%
36
1.5%
33
1.6%
37
1.7%
38
1.6%
38
1.2%
28
Phenicols Chloramphenicol
(MIC ≥ 32)
8.6%
172
10.1%
187
7.6%
136
7.8%
159
6.4%
139
7.3%
156
6.1%
146
5.7%
125
5.0%
122
4.4%
103
Tetracyclines Tetracycline
(MIC ≥ 16)
14.9%
298
16.3%
302
13.6%
242
13.9%
282
13.5%
293
14.5%
310
11.5%
275
11.9%
261
11.0%
270
10.5%
245
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 9.  Resistance patterns of non-typhoidal Salmonella isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
1998 1855 1782 2036 2171 2145 2384 2193 2449 2344
79.1% 78.0% 79.9% 80.9% 80.5% 81.1% 83.9% 83.2% 84.6% 84.6%
1580 1447 1424 1648 1748 1739 2000 1824 2073 1983
20.9% 22.0% 20.1% 19.1% 19.5% 18.9% 16.1% 16.8% 15.4% 15.4%
418 408 358 388 423 406 384 369 376 361
15.8% 17.6% 15.0% 14.8% 14.7% 14.2% 12.5% 13.0% 11.3% 11.1%
315 326 267 302 320 305 298 284 276 260
12.3% 14.2% 11.4% 12.0% 11.8% 11.1% 9.6% 9.6% 9.2% 9.1%
245 263 204 244 256 239 228 211 225 213
9.8% 11.4% 9.3% 9.1% 8.2% 8.2% 7.4% 7.3% 6.8% 6.5%
195 211 165 185 177 176 177 159 166 152
8.2% 9.8% 8.0% 7.2% 6.3% 6.9% 6.6% 6.2% 5.2% 4.6%
164 182 142 146 137 149 157 137 128 108
7.8% 9.3% 7.2% 6.9% 5.6% 6.3% 5.8% 5.1% 4.4% 3.9%
156 173 129 141 121 136 138 112 107 91
1.1% 1.2% 0.6% 0.9% 0.7% 0.7% 0.5% 0.7% 0.4% 0.4%
21 23 10 18 15 16 11 15 11 9
3.4% 3.2% 2.4% 2.0% 2.0% 2.1% 1.8% 1.4% 1.3% 1.5%
67 60 42 41 43 46 44 30 33 36
0.2% 0.1% 0.1% 0.0% 0.2% 0.2% 0.0% 0.2% 0.1% 0.1%
4 1 2 1 4 5 1 4 2 2
*
†
‡
§
At least ACSSuTAuCx§
At least ceftriaxone and nalidixic acid 
resistant
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
At least ACT/S‡
CLSI: Clinical and Laboratory Standards Institute; starting in 2011, testing included nine classes with the addition of the macrolide azithromycin
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
Resistance ≥ 1 CLSI class*
Year
Total Isolates
Resistance Pattern
No resistance detected 
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A. Salmonella ser. Enteritidis 
 
Table 10.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Enteritidis isolates 
to antimicrobial agents, 2011 (N=391) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.5 [0.1 - 1.8] 24.6 70.3 4.3 0.3 0.3 0.3
Kanamycin 0.0 0.3 [0.0 - 1.4] 99.7 0.3
Streptomycin N/A 1.8 [0.7 - 3.7] 98.2 0.5 1.3
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 0.3 [0.0 - 1.4] 91.8 3.1 4.9 0.3
Cephems Ceftiofur 0.0 0.3 [0.0 - 1.4] 0.3 0.3 10.2 87.7 1.3 0.3
Ceftriaxone 0.0 0.3 [0.0 - 1.4] 99.7 0.3
Macrolide Azithromycin N/A 0.0 [0.0 - 0.9] 0.3 0.3 15.6 81.3 2.3 0.3
Penicillins Ampicillin 0.0 5.1 [3.2 - 7.8] 87.0 7.2 0.8 5.1
Quinolones Ciprofloxacin 7.2 0.0 [0.0 - 0.9] 72.6 19.4 0.8 4.1 3.1
Nalidixic acid N/A 7.2 [4.8 - 10.2] 0.5 20.7 70.1 1.3 0.3 7.2
Cephems Cefoxitin 0.5 0.3 [0.0 - 1.4] 0.3 24.6 69.1 4.6 0.8 0.5 0.3
Folate pathway inhibitors Sulfisoxazole N/A 2.0 [0.9 - 4.0] 5.1 47.6 45.0 0.3 2.0
Trimethoprim-sulfamethoxazole N/A 0.5 [0.1 - 1.8] 99.0 0.5 0.5
Phenicols Chloramphenicol 0.3 0.0 [0.0 - 0.9] 0.5 58.3 40.9 0.3
Tetracyclines Tetracycline 0.8 1.8 [0.7 - 3.7] 97.4 0.8 0.3 1.5
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Figure 4.  Antimicrobial resistance pattern for Salmonella ser. Enteritidis, 2011 
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Table 11.  Percentage and number of Salmonella ser. Enteritidis isolates resistant to antimicrobial agents, 
2002–2011 
2002
337
2003
257
2004
271
2005
384
2006
412
2007
385
2008
441
2009
410
2010
513
2011
391
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
0.3%
1
0.4%
1
0.4%
1
0.8%
3
0.2%
1
0.0%
0
0.2%
1
0.0%
0
0.2%
1
0.5%
2
Kanamycin
(MIC ≥ 64)
0.3%
1
0.0%
0
0.7%
2
0.3%
1
0.2%
1
0.5%
2
0.0%
0
0.2%
1
0.2%
1
0.3%
1
Streptomycin
(MIC ≥ 64)
1.5%
5
1.2%
3
2.2%
6
1.0%
4
1.2%
5
0.5%
2
0.5%
2
1.2%
5
0.6%
3
1.8%
7
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
0.6%
2
0.0%
0
0.0%
0
0.8%
3
0.5%
2
0.5%
2
0.0%
0
0.0%
0
0.4%
2
0.3%
1
Ceftiofur
(MIC ≥ 8)
0.0%
0
0.0%
0
0.0%
0
0.5%
2
0.5%
2
0.3%
1
0.2%
1
0.0%
0
0.0%
0
0.3%
1
Ceftriaxone
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
0.3%
1
0.5%
2
0.3%
1
0.2%
1
0.0%
0
0.0%
0
0.3%
1
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
6.8%
23
2.3%
6
4.1%
11
2.9%
11
4.1%
17
2.1%
8
3.9%
17
3.9%
16
2.3%
12
5.1%
20
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.4%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.2%
1
0.0%
0
Nalidixic Acid
(MIC ≥ 32)
3.9%
13
4.7%
12
6.6%
18
4.7%
18
7.0%
29
5.7%
22
7.0%
31
3.7%
15
5.3%
27
7.2%
28
Cefoxitin
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
1.0%
4
0.5%
2
0.3%
1
0.0%
0
0.0%
0
0.0%
0
0.3%
1
Cephalothin
(MIC ≥ 32)
0.6%
2
1.2%
3
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
1.5%
5
1.2%
3
1.8%
5
1.6%
6
1.5%
6
1.6%
6
1.1%
5
1.7%
7
1.9%
10
2.0%
8
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
0.6%
2
0.8%
2
0.0%
0
0.5%
2
0.5%
2
1.0%
4
0.9%
4
0.7%
3
1.0%
5
0.5%
2
Phenicols Chloramphenicol
(MIC ≥ 32)
0.3%
1
0.4%
1
0.4%
1
0.5%
2
0.0%
0
0.5%
2
0.5%
2
0.0%
0
0.6%
3
0.0%
0
Tetracyclines Tetracycline
(MIC ≥ 16)
4.2%
14
1.6%
4
3.3%
9
2.3%
9
1.7%
7
3.9%
15
1.8%
8
1.2%
5
2.1%
11
1.8%
7
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 12.  Resistance patterns of Salmonella ser. Enteritidis isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
337 257 271 384 412 385 441 410 513 391
87.5% 91.8% 86.7% 91.4% 88.8% 90.4% 87.5% 92.0% 92.0% 88.0%
295 236 235 351 366 348 386 377 472 344
12.5% 8.2% 13.3% 8.6% 11.2% 9.6% 12.5% 8.0% 8.0% 12.0%
42 21 36 33 46 37 55 33 41 47
3.9% 2.3% 3.0% 3.6% 2.9% 3.4% 2.0% 2.4% 2.9% 2.6%
13 6 8 14 12 13 9 10 15 10
2.1% 0.4% 1.1% 1.6% 1.7% 1.0% 0.5% 1.0% 2.1% 2.3%
7 1 3 6 7 4 2 4 11 9
0.6% 0.4% 0.7% 1.0% 0.7% 0.3% 0.0% 0.5% 0.4% 1.3%
2 1 2 4 3 1 0 2 2 5
0.0% 0.4% 0.7% 0.5% 0.2% 0.3% 0.0% 0.2% 0.0% 0.5%
0 1 2 2 1 1 0 1 0 2
0.0% 0.4% 0.4% 0.5% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0%
0 1 1 2 0 1 0 0 0 0
0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 1 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.3% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0%
0 0 0 1 0 1 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.2% 0.0% 0.0% 0.0%
0 0 0 0 0 1 1 0 0 0
*
†
‡
§
At least ACSSuTAuCx§
At least ceftriaxone and nalidixic acid 
resistant
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
At least ACT/S‡
CLSI: Clinical and Laboratory Standards Institute; starting in 2011, testing included nine classes with the addition of the macrolide azithromycin
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
Resistance ≥ 1 CLSI class*
Year
Total Isolates
Resistance Pattern
No resistance detected 
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B. Salmonella ser. Typhimurium 
 
Table 13.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhimurium 
isolates to antimicrobial agents, 2011 (N=323) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 2.2 [0.9 - 4.4] 3.1 78.3 16.1 0.3 2.2
Kanamycin 0.0 4.0 [2.2 - 6.8] 96.0 4.0
Streptomycin N/A 25.7 [21.0 - 30.8] 74.3 5.0 20.7
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 12.1 6.8 [4.3 - 10.1] 73.4 0.6 1.2 5.9 12.1 1.5 5.3
Cephems Ceftiofur 0.0 6.8 [4.3 - 10.1] 0.3 30.0 62.2 0.6 0.6 6.2
Ceftriaxone 0.0 6.8 [4.3 - 10.1] 93.2 0.3 0.9 3.7 1.5 0.3
Macrolide Azithromycin N/A 0.0 [0.0 - 1.1] 11.8 83.0 5.0
Penicillins Ampicillin 0.0 25.7 [21.0 - 30.8] 71.8 2.2 0.3 0.3 25.4
Quinolones Ciprofloxacin 1.9 0.0 [0.0 - 1.1] 96.0 2.2 0.3 1.5
Nalidixic acid N/A 0.3 [0.0 - 1.7] 55.1 42.4 1.5 0.6 0.3
Cephems Cefoxitin 0.3 6.8 [4.3 - 10.1] 0.3 30.7 54.2 6.2 1.5 0.3 3.4 3.4
Folate pathway inhibitors Sulfisoxazole N/A 27.2 [22.5 - 32.4] 1.5 59.1 11.8 0.3 27.2
Trimethoprim-sulfamethoxazole N/A 1.9 [0.7 - 4.0] 92.6 4.6 0.9 1.9
Phenicols Chloramphenicol 0.3 19.5 [15.3 - 24.3] 0.9 42.7 36.5 0.3 19.5
Tetracyclines Tetracycline 0.0 27.2 [22.5 - 32.4] 72.8 0.9 10.5 15.8
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Figure 5.  Antimicrobial resistance pattern for Salmonella ser. Typhimurium, 2011
 
 
  
 
Gentamicin 
Kanamycin 
Streptomycin 
Amoxicillin-clavulanic acid 
Ceftiofur 
Ceftriaxone 
Azithromycin 
Ampicillin 
Ciprofloxacin 
Nalidixic acid 
Cefoxitin 
Sulfisoxazole 
Trimethoprim-sulfamethoxazole 
Chloramphenicol 
Tetracycline 
Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
 
35 
Table 14.  Percentage and number of Salmonella ser. Typhimurium isolates resistant to antimicrobial 
agents, 2002–2011 
2002
394
2003
408
2004
382
2005
438
2006
408
2007
405
2008
397
2009
370
2010
359
2011
323
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
2.3%
9
2.0%
8
2.1%
8
1.8%
8
2.7%
11
2.5%
10
1.5%
6
1.9%
7
0.8%
3
2.2%
7
Kanamycin
(MIC ≥ 64)
7.6%
30
7.1%
29
5.8%
22
5.7%
25
5.1%
21
5.9%
24
2.5%
10
4.9%
18
7.2%
26
4.0%
13
Streptomycin
(MIC ≥ 64)
32.0%
126
35.5%
145
31.9%
122
28.1%
123
29.4%
120
32.3%
131
28.7%
114
25.9%
96
25.6%
92
25.7%
83
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
7.6%
30
5.6%
23
4.7%
18
3.2%
14
4.4%
18
6.7%
27
3.5%
14
6.2%
23
4.2%
15
6.8%
22
Ceftiofur
(MIC ≥ 8)
4.3%
17
4.9%
20
4.5%
17
2.5%
11
4.2%
17
6.4%
26
3.5%
14
6.5%
24
4.7%
17
6.8%
22
Ceftriaxone
(MIC ≥ 4)
4.3%
17
4.9%
20
4.5%
17
2.5%
11
4.2%
17
6.4%
26
3.5%
14
6.5%
24
4.7%
17
6.8%
22
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
33.8%
133
36.3%
148
32.2%
123
29.0%
127
28.2%
115
31.6%
128
26.4%
105
28.1%
104
26.2%
94
25.7%
83
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.0%
0
0.2%
1
0.2%
1
0.0%
0
0.0%
0
0.8%
3
0.0%
0
0.0%
0
Nalidixic Acid
(MIC ≥ 32)
1.3%
5
1.2%
5
0.5%
2
0.9%
4
0.7%
3
1.5%
6
1.3%
5
2.2%
8
1.4%
5
0.3%
1
Cefoxitin
(MIC ≥ 32)
4.3%
17
4.4%
18
4.7%
18
2.5%
11
3.9%
16
5.7%
23
3.5%
14
5.4%
20
3.3%
12
6.8%
22
Cephalothin
(MIC ≥ 32)
5.6%
22
6.1%
25
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
32.2%
127
38.7%
158
36.1%
138
32.0%
140
33.3%
136
37.3%
151
30.5%
121
30.0%
111
28.7%
103
27.2%
88
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
2.3%
9
3.4%
14
2.6%
10
2.7%
12
2.2%
9
2.5%
10
1.8%
7
3.0%
11
1.9%
7
1.9%
6
Phenicols Chloramphenicol
(MIC ≥ 32)
23.4%
92
28.2%
115
24.3%
93
24.4%
107
22.1%
90
25.4%
103
23.4%
93
20.5%
76
20.3%
73
19.5%
63
Tetracyclines Tetracycline
(MIC ≥ 16)
32.0%
126
38.0%
155
30.4%
116
30.4%
133
31.6%
129
36.8%
149
27.7%
110
28.9%
107
29.0%
104
27.2%
88
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 15.  Resistance patterns of Salmonella ser. Typhimurium isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
394 408 382 438 408 405 397 370 359 323
59.9% 54.7% 60.5% 65.1% 62.5% 57.5% 67.8% 63.5% 66.9% 69.0%
236 223 231 285 255 233 269 235 240 223
40.1% 45.3% 39.5% 34.9% 37.5% 42.5% 32.2% 36.5% 33.1% 31.0%
158 185 151 153 153 172 128 135 119 100
36.3% 41.4% 37.2% 33.3% 34.1% 39.3% 31.5% 33.2% 30.4% 28.8%
143 169 142 146 139 159 125 123 109 93
32.5% 37.3% 31.7% 30.1% 30.4% 34.3% 28.0% 28.1% 27.3% 26.3%
128 152 121 132 124 139 111 104 98 85
28.4% 32.4% 27.7% 27.4% 27.0% 29.9% 24.9% 24.1% 24.2% 21.7%
112 132 106 120 110 121 99 89 87 70
23.1% 27.7% 24.3% 22.8% 20.8% 24.9% 23.9% 22.2% 20.9% 20.7%
91 113 93 100 85 101 95 82 75 67
21.6% 26.5% 23.6% 22.4% 19.6% 22.7% 23.2% 19.5% 18.7% 19.5%
85 108 90 98 80 92 92 72 67 63
2.0% 3.2% 1.6% 2.1% 0.7% 2.0% 0.5% 2.2% 1.1% 0.6%
8 13 6 9 3 8 2 8 4 2
1.8% 2.2% 2.6% 1.8% 2.9% 3.7% 2.3% 1.6% 1.7% 5.3%
7 9 10 8 12 15 9 6 6 17
0.5% 0.0% 0.0% 0.0% 0.0% 0.2% 0.0% 0.5% 0.3% 0.0%
2 0 0 0 0 1 0 2 1 0
*
†
‡
§
At least ACSSuTAuCx§
At least ceftriaxone and nalidixic acid 
resistant
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
At least ACT/S‡
CLSI: Clinical and Laboratory Standards Institute; starting in 2011, testing included nine classes with the addition of the macrolide azithromycin
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
Resistance ≥ 1 CLSI class*
Year
Total Isolates
Resistance Pattern
No resistance detected 
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C. Salmonella ser. Newport 
 
Table 16.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Newport isolates 
to antimicrobial agents, 2011 (N=285) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.7 [0.1 - 2.5] 2.5 86.3 10.2 0.4 0.7
Kanamycin 0.0 0.4 [0.0 - 1.9] 99.6 0.4
Streptomycin N/A 4.2 [2.2 - 7.2] 95.8 0.4 3.9
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 3.9 [1.9 - 6.8] 95.4 0.7 1.4 2.5
Cephems Ceftiofur 0.0 3.9 [1.9 - 6.8] 0.4 31.6 63.2 1.1 3.9
Ceftriaxone 0.0 3.9 [1.9 - 6.8] 96.1 0.4 0.7 2.5 0.4
Macrolide Azithromycin N/A 0.0 [0.0 - 1.3] 0.4 0.4 18.2 78.6 2.5
Penicillins Ampicillin 0.4 3.9 [1.9 - 6.8] 93.3 2.5 0.4 3.9
Quinolones Ciprofloxacin 0.4 0.0 [0.0 - 1.3] 99.3 0.4 0.4
Nalidixic acid N/A 0.4 [0.0 - 1.9] 0.4 0.4 50.2 48.8 0.4
Cephems Cefoxitin 0.4 3.9 [1.9 - 6.8] 0.7 30.5 60.7 3.9 0.4 0.4 3.5
Folate pathway inhibitors Sulfisoxazole N/A 4.6 [2.4 - 7.7] 0.7 26.7 63.9 4.2 4.6
Trimethoprim-sulfamethoxazole N/A 0.0 [0.0 - 1.3] 99.6 0.4
Phenicols Chloramphenicol 0.0 3.5 [1.7 - 6.4] 0.7 83.2 12.6 3.5
Tetracyclines Tetracycline 0.0 4.6 [2.4 - 7.7] 95.4 4.6
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Figure 6.  Antimicrobial resistance pattern for Salmonella ser. Newport, 2011 
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Table 17.  Percentage and number of Salmonella ser. Newport isolates resistant to antimicrobial agents, 
2002–2011 
2002
244
2003
226
2004
191
2005
207
2006
218
2007
222
2008
258
2009
238
2010
305
2011
285
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
3.3%
8
3.1%
7
0.5%
1
1.0%
2
0.9%
2
0.9%
2
0.4%
1
0.4%
1
0.3%
1
0.7%
2
Kanamycin
(MIC ≥ 64)
9.8%
24
4.4%
10
2.6%
5
1.9%
4
2.3%
5
0.9%
2
3.5%
9
1.7%
4
0.7%
2
0.4%
1
Streptomycin
(MIC ≥ 64)
25.0%
61
24.3%
55
15.7%
30
14.0%
29
13.8%
30
10.4%
23
13.6%
35
8.4%
20
8.2%
25
4.2%
12
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
22.5%
55
21.7%
49
15.2%
29
12.6%
26
12.4%
27
8.1%
18
12.4%
32
7.6%
18
7.5%
23
3.9%
11
Ceftiofur
(MIC ≥ 8)
22.5%
55
22.1%
50
15.2%
29
12.6%
26
12.4%
27
8.1%
18
12.4%
32
7.1%
17
7.2%
22
3.9%
11
Ceftriaxone
(MIC ≥ 4)
22.5%
55
21.7%
49
14.7%
28
12.6%
26
12.8%
28
8.1%
18
12.4%
32
7.1%
17
7.2%
22
3.9%
11
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
24.6%
60
23.0%
52
15.7%
30
14.0%
29
15.1%
33
9.9%
22
14.3%
37
8.4%
20
7.5%
23
3.9%
11
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Nalidixic Acid
(MIC ≥ 32)
0.8%
2
0.4%
1
0.5%
1
0.0%
0
0.9%
2
0.0%
0
0.4%
1
0.0%
0
0.3%
1
0.4%
1
Cefoxitin
(MIC ≥ 32)
22.1%
54
21.7%
49
15.2%
29
12.6%
26
12.8%
28
8.1%
18
12.4%
32
6.7%
16
7.2%
22
3.9%
11
Cephalothin
(MIC ≥ 32)
22.5%
55
22.6%
51
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
25.4%
62
24.8%
56
16.8%
32
15.5%
32
15.1%
33
10.4%
23
13.2%
34
8.8%
21
7.5%
23
4.6%
13
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
4.1%
10
1.3%
3
2.1%
4
1.9%
4
3.2%
7
1.8%
4
3.1%
8
1.3%
3
1.3%
4
0.0%
0
Phenicols Chloramphenicol
(MIC ≥ 32)
25.0%
61
22.6%
51
15.2%
29
13.5%
28
12.4%
27
9.5%
21
12.0%
31
7.6%
18
7.2%
22
3.5%
10
Tetracyclines Tetracycline
(MIC ≥ 16)
25.4%
62
24.3%
55
16.8%
32
14.5%
30
14.2%
31
9.9%
22
14.0%
36
8.8%
21
8.2%
25
4.6%
13
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 18.  Resistance patterns of Salmonella ser. Newport isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
244 226 191 207 218 222 258 238 305 285
72.5% 73.5% 82.2% 84.1% 82.6% 89.2% 85.3% 89.1% 90.8% 94.4%
177 166 157 174 180 198 220 212 277 269
27.5% 26.5% 17.8% 15.9% 17.4% 10.8% 14.7% 10.9% 9.2% 5.6%
67 60 34 33 38 24 38 26 28 16
25.0% 25.2% 17.3% 15.0% 16.5% 10.8% 13.6% 9.2% 7.9% 4.6%
61 57 33 31 36 24 35 22 24 13
25.0% 23.5% 16.2% 14.5% 15.1% 10.8% 13.6% 8.4% 7.5% 3.9%
61 53 31 30 33 24 35 20 23 11
25.0% 23.0% 15.7% 14.0% 13.3% 9.5% 13.6% 7.6% 7.5% 3.9%
61 52 30 29 29 21 35 18 23 11
23.4% 22.6% 14.7% 12.6% 12.8% 8.6% 12.8% 7.1% 7.2% 3.5%
57 51 28 26 28 19 33 17 22 10
23.4% 22.1% 14.7% 12.6% 11.9% 8.6% 11.6% 7.1% 7.2% 3.5%
57 50 28 26 26 19 30 17 22 10
3.7% 1.3% 1.0% 1.9% 2.3% 0.5% 2.7% 1.3% 1.3% 0.0%
9 3 2 4 5 1 7 3 4 0
22.5% 21.2% 14.7% 12.6% 10.6% 8.1% 11.6% 7.1% 7.2% 3.5%
55 48 28 26 23 18 30 17 22 10
0.4% 0.0% 0.5% 0.0% 0.5% 0.0% 0.0% 0.0% 0.0% 0.4%
1 0 1 0 1 0 0 0 0 1
*
†
‡
§
At least ACSSuTAuCx§
At least ceftriaxone and nalidixic acid 
resistant
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
At least ACT/S‡
CLSI: Clinical and Laboratory Standards Institute; starting in 2011, testing included nine classes with the addition of the macrolide azithromycin
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
Resistance ≥ 1 CLSI class*
Year
Total Isolates
Resistance Pattern
No resistance detected 
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D. Salmonella ser. Heidelberg  
 
Table 19.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Heidelberg 
isolates to antimicrobial agents, 2011 (N=70) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 20.0 [11.4 - 31.3] 8.6 48.6 22.9 20.0
Kanamycin 0.0 21.4 [12.5 - 32.9] 75.7 2.9 1.4 20.0
Streptomycin N/A 37.1 [25.9 - 49.5] 62.9 12.9 24.3
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 1.4 10.0 [4.1 - 19.5] 68.6 1.4 18.6 1.4 2.9 7.1
Cephems Ceftiofur 1.4 8.6 [3.2 - 17.7] 1.4 51.4 34.3 2.9 1.4 8.6
Ceftriaxone 1.4 8.6 [3.2 - 17.7] 90.0 1.4 5.7 1.4 1.4
Macrolide Azithromycin N/A 0.0 [0.0 - 5.1] 1.4 1.4 90.0 7.1
Penicillins Ampicillin 0.0 30.0 [19.6 - 42.1] 68.6 1.4 1.4 28.6
Quinolones Ciprofloxacin 0.0 0.0 [0.0 - 5.1] 98.6 1.4
Nalidixic acid N/A 0.0 [0.0 - 5.1] 1.4 44.3 52.9 1.4
Cephems Cefoxitin 0 8.6 [3.2 - 17.7] 1.4 54.3 31.4 1.4 2.9 4.3 4.3
Folate pathway inhibitors Sulfisoxazole N/A 7.1 [2.3 - 15.9] 21.4 61.4 10.0 7.1
Trimethoprim-sulfamethoxazole N/A 1.4 [0.0 - 7.7] 98.6 1.4
Phenicols Chloramphenicol 1.4 4.3 [0.9 - 12.0] 1.4 27.1 65.7 1.4 1.4 2.9
Tetracyclines Tetracycline 0.0 34.3 [23.3 - 46.6] 65.7 34.3
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Figure 7.  Antimicrobial resistance pattern for Salmonella ser. Heidelberg, 2011 
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Table 20.  Percentage and number of Salmonella ser. Heidelberg isolates resistant to antimicrobial 
agents, 2002–2011 
2002
105
2003
96
2004
92
2005
125
2006
102
2007
98
2008
75
2009
86
2010
62
2011
70
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
3.8%
4
5.2%
5
4.3%
4
6.4%
8
4.9%
5
16.3%
16
14.7%
11
2.3%
2
8.1%
5
20.0%
14
Kanamycin
(MIC ≥ 64)
10.5%
11
8.3%
8
8.7%
8
12.8%
16
8.8%
9
11.2%
11
26.7%
20
20.9%
18
21.0%
13
21.4%
15
Streptomycin
(MIC ≥ 64)
17.1%
18
12.5%
12
15.2%
14
13.6%
17
11.8%
12
12.2%
12
30.7%
23
23.3%
20
25.8%
16
37.1%
26
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
9.5%
10
5.2%
5
9.8%
9
8.8%
11
9.8%
10
7.1%
7
8.0%
6
20.9%
18
24.2%
15
10.0%
7
Ceftiofur
(MIC ≥ 8)
7.6%
8
5.2%
5
8.7%
8
8.8%
11
9.8%
10
7.1%
7
8.0%
6
20.9%
18
24.2%
15
8.6%
6
Ceftriaxone
(MIC ≥ 4)
7.6%
8
5.2%
5
8.7%
8
8.8%
11
9.8%
10
7.1%
7
8.0%
6
20.9%
18
24.2%
15
8.6%
6
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
12.4%
13
10.4%
10
25.0%
23
20.0%
25
18.6%
19
18.4%
18
28.0%
21
27.9%
24
38.7%
24
30.0%
21
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Nalidixic Acid
(MIC ≥ 32)
0.0%
0
1.0%
1
0.0%
0
0.8%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Cefoxitin
(MIC ≥ 32)
8.6%
9
5.2%
5
7.6%
7
8.8%
11
8.8%
9
7.1%
7
8.0%
6
19.8%
17
24.2%
15
8.6%
6
Cephalothin
(MIC ≥ 32)
10.5%
11
7.3%
7
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
6.7%
7
7.3%
7
7.6%
7
8.0%
10
4.9%
5
18.4%
18
12.0%
9
7.0%
6
11.3%
7
7.1%
5
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
1.0%
1
2.1%
2
0.0%
0
0.8%
1
0.0%
0
0.0%
0
2.7%
2
3.5%
3
0.0%
0
1.4%
1
Phenicols Chloramphenicol
(MIC ≥ 32)
1.0%
1
0.0%
0
1.1%
1
0.8%
1
0.0%
0
3.1%
3
1.3%
1
4.7%
4
1.6%
1
4.3%
3
Tetracyclines Tetracycline
(MIC ≥ 16)
19.0%
20
16.7%
16
19.6%
18
18.4%
23
13.7%
14
22.4%
22
36.0%
27
27.9%
24
22.6%
14
34.3%
24
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 21.  Resistance patterns of Salmonella ser. Heidelberg isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
105 96 92 125 102 98 75 86 62 70
67.6% 68.8% 56.5% 62.4% 67.6% 58.2% 57.3% 60.5% 53.2% 55.7%
71 66 52 78 69 57 43 52 33 39
32.4% 31.3% 43.5% 37.6% 32.4% 41.8% 42.7% 39.5% 46.8% 44.3%
34 30 40 47 33 41 32 34 29 31
25.7% 17.7% 22.8% 24.8% 23.5% 28.6% 40.0% 34.9% 41.9% 44.3%
27 17 21 31 24 28 30 30 26 31
12.4% 10.4% 13.0% 15.2% 12.7% 17.3% 28.0% 25.6% 33.9% 30.0%
13 10 12 19 13 17 21 22 21 21
1.9% 0.0% 4.3% 4.8% 2.0% 5.1% 13.3% 17.4% 11.3% 4.3%
2 0 4 6 2 5 10 15 7 3
1.9% 0.0% 3.3% 1.6% 2.0% 4.1% 6.7% 15.1% 9.7% 4.3%
2 0 3 2 2 4 5 13 6 3
1.0% 0.0% 1.1% 0.0% 0.0% 3.1% 1.3% 3.5% 1.6% 1.4%
1 0 1 0 0 3 1 3 1 1
1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 3.5% 0.0% 1.4%
1 0 0 0 0 0 0 3 0 1
1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.2% 0.0% 1.4%
1 0 0 0 0 0 0 1 0 1
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
*
†
‡
§
Resistance ≥ 1 CLSI class*
Year
Total Isolates
Resistance Pattern
No resistance detected 
At least ACSSuTAuCx§
At least ceftriaxone and nalidixic acid 
resistant
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
At least ACT/S‡
CLSI: Clinical and Laboratory Standards Institute; starting in 2011, testing included nine classes with the addition of the macrolide azithromycin
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
 
  
 
40 
E. Salmonella ser. I 4,[5],12:i:- 
 
Table 22.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. I 4,[5],12:i:- 
isolates to antimicrobial agents, 2011 (N=82) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 1.2 [0.0 - 6.6] 2.4 85.4 11.0 1.2
Kanamycin 0.0 0.0 [0.0 - 4.4] 100.0
Streptomycin N/A 24.4 [15.6 - 35.1] 75.6 1.2 23.2
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 4.9 [1.3 - 12.0] 69.5 2.4 4.9 18.3 1.2 3.7
Cephems Ceftiofur 0.0 3.7 [0.7 - 10.3] 2.4 37.8 54.9 1.2 3.7
Ceftriaxone 0.0 3.7 [0.7 - 10.3] 96.3 2.4 1.2
Macrolide Azithromycin N/A 0.0 [0.0 - 4.4] 8.5 84.1 6.1 1.2
Penicillins Ampicillin 0.0 26.8 [17.6 - 37.8] 69.5 1.2 2.4 26.8
Quinolones Ciprofloxacin 0.0 0.0 [0.0 - 4.4] 97.6 2.4
Nalidixic acid N/A 0.0 [0.0 - 4.4] 59.8 39.0 1.2
Cephems Cefoxitin 0.0 4.9 [1.3 - 12.0] 1.2 39.0 51.2 2.4 1.2 3.7 1.2
Folate pathway inhibitors Sulfisoxazole N/A 23.2 [14.6 - 33.8] 2.4 50.0 24.4 23.2
Trimethoprim-sulfamethoxazole N/A 1.2 [0.0 - 6.6] 98.8 1.2
Phenicols Chloramphenicol 1.2 2.4 [0.3 - 8.5] 1.2 56.1 39.0 1.2 2.4
Tetracyclines Tetracycline 0.0 25.6 [16.6 - 36.4] 74.4 25.6
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Figure 8.  Antimicrobial resistance pattern for Salmonella ser. I 4,[5],12:i:-, 2011 
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Table 23.  Percentage and number of Salmonella ser. I 4,[5],12:i:- isolates resistant to antimicrobial 
agents, 2002–2011 
2002
35
2003
36
2004
36
2005
33
2006
105
2007
73
2008
84
2009
72
2010
78
2011
82
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
5.6%
2
5.6%
2
0.0%
0
4.8%
5
1.4%
1
3.6%
3
2.8%
2
1.3%
1
1.2%
1
Kanamycin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.4%
1
1.2%
1
0.0%
0
1.3%
1
0.0%
0
Streptomycin
(MIC ≥ 64)
2.9%
1
8.3%
3
5.6%
2
3.0%
1
3.8%
4
8.2%
6
10.7%
9
12.5%
9
19.2%
15
24.4%
20
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
2.9%
1
5.6%
2
2.8%
1
3.0%
1
3.8%
4
1.4%
1
4.8%
4
4.2%
3
3.8%
3
4.9%
4
Ceftiofur
(MIC ≥ 8)
2.9%
1
5.6%
2
2.8%
1
3.0%
1
3.8%
4
2.7%
2
4.8%
4
2.8%
2
2.6%
2
3.7%
3
Ceftriaxone
(MIC ≥ 4)
2.9%
1
5.6%
2
2.8%
1
3.0%
1
3.8%
4
2.7%
2
4.8%
4
2.8%
2
2.6%
2
3.7%
3
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
8.6%
3
8.3%
3
5.6%
2
6.1%
2
6.7%
7
5.5%
4
9.5%
8
11.1%
8
21.8%
17
26.8%
22
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.3%
1
0.0%
0
Nalidixic Acid
(MIC ≥ 32)
0.0%
0
2.8%
1
2.8%
1
0.0%
0
1.0%
1
1.4%
1
1.2%
1
0.0%
0
2.6%
2
0.0%
0
Cefoxitin
(MIC ≥ 32)
2.9%
1
5.6%
2
2.8%
1
3.0%
1
3.8%
4
1.4%
1
4.8%
4
2.8%
2
2.6%
2
4.9%
4
Cephalothin
(MIC ≥ 32)
2.9%
1
5.6%
2
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
2.9%
1
5.6%
2
11.1%
4
0.0%
0
8.6%
9
4.1%
3
13.1%
11
13.9%
10
19.2%
15
23.2%
19
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
2.9%
1
0.0%
0
2.8%
1
0.0%
0
0.0%
0
1.4%
1
4.8%
4
1.4%
1
1.3%
1
1.2%
1
Phenicols Chloramphenicol
(MIC ≥ 32)
2.9%
1
0.0%
0
2.8%
1
0.0%
0
1.9%
2
1.4%
1
6.0%
5
8.3%
6
1.3%
1
2.4%
2
Tetracyclines Tetracycline
(MIC ≥ 16)
5.7%
2
0.0%
0
11.1%
4
3.0%
1
8.6%
9
9.6%
7
16.7%
14
16.7%
12
28.2%
22
25.6%
21
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 24.  Resistance patterns* of Salmonella ser. I 4,[5],12:i:- isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
35 36 36 33 105 73 84 72 78 82
91.4% 77.8% 80.6% 87.9% 85.7% 82.2% 76.2% 76.4% 66.7% 65.9%
32 28 29 29 90 60 64 55 52 54
8.6% 22.2% 19.4% 12.1% 14.3% 17.8% 23.8% 23.6% 33.3% 34.1%
3 8 7 4 15 13 20 17 26 28
8.6% 11.1% 13.9% 3.0% 11.4% 6.8% 17.9% 16.7% 21.8% 28.0%
3 4 5 1 12 5 15 12 17 23
5.7% 5.6% 8.3% 3.0% 9.5% 5.5% 10.7% 12.5% 21.8% 26.8%
2 2 3 1 10 4 9 9 17 22
2.9% 0.0% 2.8% 0.0% 3.8% 2.7% 7.1% 9.7% 19.2% 20.7%
1 0 1 0 4 2 6 7 15 17
2.9% 0.0% 2.8% 0.0% 2.9% 1.4% 4.8% 6.9% 3.8% 1.2%
1 0 1 0 3 1 4 5 3 1
2.9% 0.0% 2.8% 0.0% 1.9% 1.4% 3.6% 6.9% 1.3% 1.2%
1 0 1 0 2 1 3 5 1 1
2.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
1 0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 2.4% 0.0% 0.0% 0.0%
0 0 0 0 0 0 2 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
*
†
‡
§
¶
Resistance ≥ 1 CLSI class†
Year
Total Isolates
Resistance Pattern
No resistance detected 
At least ACSSuTAuCx¶
At least ceftriaxone and nalidixic acid 
resistant
Emerging resistance to ASSuT (ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline, but not chloramphenicol) in 
Salmonella  ser. I 4,[5],12:i:- is described on page 16 of this report
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone
Resistance ≥ 2 CLSI classes†
Resistance ≥ 3 CLSI classes†
Resistance ≥ 4 CLSI classes†
Resistance ≥ 5 CLSI classes†
At least ACSSuT‡ 
At least ACT/S§
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2. Typhoidal Salmonella 
 
A. Salmonella ser. Typhi 
 
Table 25.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhi isolates to 
antimicrobial agents, 2011 (N=383) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 1.0] 55.1 43.3 1.6
Kanamycin 0.0 0.0 [0.0 - 1.0] 100.0
Streptomycin N/A 10.7 [7.8 - 14.2] 89.3 0.3 10.4
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 0.0 [0.0 - 1.0] 88.3 0.5 3.1 8.1
Cephems Ceftiofur 0.0 0.0 [0.0 - 1.0] 0.5 2.1 81.5 15.9
Ceftriaxone 0.3 0.0 [0.0 - 1.0] 99.7 0.3
Macrolide Azithromycin N/A 0.0 [0.0 - 1.0] 0.3 2.9 43.3 52.2 1.3
Penicillins Ampicillin 0.0 11.2 [8.2 - 14.8] 88.5 0.3 11.2
Quinolones Ciprofloxacin 64.2 7.3 [4.9 - 10.4] 26.1 0.3 2.1 12.0 42.3 9.9 0.5 6.8
Nalidixic acid N/A 70.8 [65.9 - 75.3] 6.5 17.5 4.2 1.0 1.8 68.9
Cephems Cefoxitin 0.0 0.0 [0.0 - 1.0] 3.7 27.2 12.3 52.0 5.0
Folate pathway inhibitors Sulfisoxazole N/A 12.0 [8.9 - 15.7] 19.8 50.4 12.5 5.0 0.3 12.0
Trimethoprim-sulfamethoxazole N/A 11.7 [8.7 - 15.4] 88.0 0.3 11.7
Phenicols Chloramphenicol 0.3 10.7 [7.8 - 14.2] 3.7 68.4 17.0 0.3 10.7
Tetracyclines Tetracycline 0.0 4.4 [2.6 - 7.0] 95.6 0.3 4.2
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Figure 9.  Antimicrobial resistance pattern for Salmonella ser. Typhi, 2011 
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Table 26.  Percentage and number of Salmonella ser. Typhi isolates resistant to antimicrobial agents, 
2002–2011 
2002
195
2003
332
2004
304
2005
318
2006
323
2007
400
2008
407
2009
363
2010
446
2011
383
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Kanamycin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.2%
1
0.0%
0
Streptomycin
(MIC ≥ 64)
7.2%
14
14.5%
48
11.8%
36
13.2%
42
18.9%
61
15.8%
63
11.5%
47
10.7%
39
10.1%
45
10.7%
41
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.3%
1
0.3%
1
0.0%
0
0.3%
1
0.0%
0
0.0%
0
Ceftiofur
(MIC ≥ 8)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Ceftriaxone
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
5.6%
11
16.0%
53
11.8%
36
13.2%
42
20.4%
66
17.0%
68
13.0%
53
12.7%
46
12.3%
55
11.2%
43
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.3%
1
0.0%
0
0.3%
1
0.9%
3
2.0%
8
0.7%
3
3.9%
14
4.3%
19
7.3%
28
Nalidixic Acid
(MIC ≥ 32)
23.6%
46
37.7%
125
41.8%
127
48.4%
154
54.5%
176
62.0%
248
59.0%
240
59.8%
217
69.3%
309
70.8%
271
Cefoxitin
(MIC ≥ 32)
0.0%
0
0.3%
1
0.0%
0
0.0%
0
0.3%
1
0.5%
2
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Cephalothin
(MIC ≥ 32)
1.5%
3
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
6.2%
12
16.9%
56
11.8%
36
14.2%
45
20.7%
67
17.5%
70
13.0%
53
13.8%
50
12.3%
55
12.0%
46
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
6.7%
13
16.9%
56
13.2%
40
14.5%
46
20.7%
67
16.3%
65
12.5%
51
12.7%
46
11.9%
53
11.7%
45
Phenicols Chloramphenicol
(MIC ≥ 32)
6.2%
12
16.6%
55
13.2%
40
13.2%
42
19.5%
63
15.8%
63
12.8%
52
11.8%
43
11.7%
52
10.7%
41
Tetracyclines Tetracycline
(MIC ≥ 16)
6.7%
13
15.4%
51
8.9%
27
10.1%
32
8.4%
27
6.3%
25
4.4%
18
6.1%
22
3.6%
16
4.4%
17
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 27.  Resistance patterns of Salmonella ser. Typhi isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
195 332 304 318 323 400 407 363 446 383
74.4% 56.6% 56.6% 48.1% 40.2% 35.5% 38.3% 37.5% 29.4% 27.9%
145 188 172 153 130 142 156 136 131 107
25.6% 43.4% 43.4% 51.9% 59.8% 64.5% 61.7% 62.5% 70.6% 72.1%
50 144 132 165 193 258 251 227 315 276
7.2% 17.5% 13.2% 14.5% 21.7% 18.0% 14.3% 14.6% 13.7% 12.5%
14 58 40 46 70 72 58 53 61 48
6.7% 16.6% 12.8% 13.8% 20.7% 17.5% 13.3% 13.2% 13.7% 12.3%
13 55 39 44 67 70 54 48 61 47
6.2% 16.3% 12.5% 12.9% 19.2% 17.0% 12.8% 12.7% 11.7% 11.2%
12 54 38 41 62 68 52 46 52 43
5.6% 14.2% 11.8% 11.9% 16.7% 14.8% 10.8% 10.2% 9.6% 9.9%
11 47 36 38 54 59 44 37 43 38
5.6% 12.7% 7.9% 9.1% 5.9% 3.8% 2.5% 2.8% 1.6% 2.3%
11 42 24 29 19 15 10 10 7 9
5.6% 15.7% 11.8% 12.9% 18.6% 15.3% 12.0% 11.0% 10.5% 10.4%
11 52 36 41 60 61 49 40 47 40
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
*
†
‡
§
Resistance ≥ 1 CLSI class*
Year
Total Isolates
Resistance Pattern
No resistance detected 
At least ACSSuTAuCx§
At least ceftriaxone and nalidixic acid 
resistant
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
At least ACT/S‡
CLSI: Clinical and Laboratory Standards Institute; starting in 2011, testing included nine classes with the addition of the macrolide azithromycin
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
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B. Salmonella  ser. Paratyphi A, Paratyphi B (tartrate negative), and Paratyphi C 
 
Table 28.  Frequency of Salmonella ser. Paratyphi A, Paratyphi B (tartrate negative), and Paratyphi C, 2011 
(see Methods for varying sampling method by serotype) 
n (%)
Paratyphi A 146 (97.3)
Paratyphi B 2 (1.3)
Paratyphi C 2 (1.3)
Total 150 (100)
Serotype 2011
 
 
 
Table 29.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Paratyphi A 
isolates to antimicrobial agents, 2011 (N=146)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 2.5] 98.6 0.7 0.7
Kanamycin 0.0 0.0 [0.0 - 2.5] 100.0
Streptomycin N/A 0.0 [0.0 - 2.5] 100.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 0.0 [0.0 - 2.5] 63.0 34.2 2.7
Cephems Ceftiofur 0.0 0.0 [0.0 - 2.5] 0.7 2.7 93.2 3.4
Ceftriaxone 0.0 0.0 [0.0 - 2.5] 100.0
Macrolide Azithromycin N/A 0.0 [0.0 - 2.5] 3.4 51.4 41.1 4.1
Penicillins Ampicillin 0.0 0.0 [0.0 - 2.5] 4.1 89.0 6.2 0.7
Quinolones Ciprofloxacin 95.2 2.1 [0.4 - 5.9] 2.1 0.7 1.4 2.1 91.8 2.1
Nalidixic acid N/A 96.6 [92.2 - 98.9] 0.7 2.1 0.7 96.6
Cephems Cefoxitin 2.1 0.0 [0.0 - 2.5] 7.5 74.0 16.4 2.1
Folate pathway inhibitors Sulfisoxazole N/A 0.0 [0.0 - 2.5] 9.6 67.1 23.3
Trimethoprim-sulfamethoxazole N/A 0.0 [0.0 - 2.5] 97.3 2.7
Phenicols Chloramphenicol 6.2 0.0 [0.0 - 2.5] 4.8 89.0 6.2
Tetracyclines Tetracycline 0.0 0.0 [0.0 - 2.5] 100.0
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
Figure 10.  Antimicrobial resistance pattern for Salmonella ser. Paratyphi A, 2011 
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Table 30.  Percentage and number of Salmonella ser. Paratyphi A isolates resistant to antimicrobial 
agents, 2002–2011
2002
9
2003
6
2004
8
2005
13
2006
10
2007
16
2008
116
2009
99
2010
145
2011
146
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.7%
1
0.0%
0
Kanamycin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.7%
1
0.0%
0
Streptomycin
(MIC ≥ 64)
11.1%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
2.1%
3
0.0%
0
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Ceftiofur
(MIC ≥ 8)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Ceftriaxone
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
1.4%
2
0.0%
0
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.9%
1
0.0%
0
2.8%
4
2.1%
3
Nalidixic Acid
(MIC ≥ 32)
44.4%
4
100.0%
6
100.0%
8
92.3%
12
80.0%
8
93.8%
15
88.8%
103
86.9%
86
92.4%
134
96.6%
141
Cefoxitin
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Cephalothin
(MIC ≥ 32)
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
1.4%
2
0.0%
0
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
2.1%
3
0.0%
0
Phenicols Chloramphenicol
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
1.4%
2
0.0%
0
Tetracyclines Tetracycline
(MIC ≥ 16)
11.1%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.9%
1
1.0%
1
1.4%
2
0.0%
0
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 31.  Resistance patterns of Salmonella ser. Paratyphi A isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
9 6 8 13 10 16 116 99 145 146
44.4% 0.0% 0.0% 7.7% 20.0% 6.3% 10.3% 12.1% 5.5% 3.4%
4 0 0 1 2 1 12 12 8 5
55.6% 100.0% 100.0% 92.3% 80.0% 93.8% 89.7% 87.9% 94.5% 96.6%
5 6 8 12 8 15 104 87 137 141
11.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0% 2.8% 0.0%
1 0 0 0 0 0 0 1 4 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0% 1.4% 0.0%
0 0 0 0 0 0 0 1 2 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0% 1.4% 0.0%
0 0 0 0 0 0 0 1 2 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0% 0.7% 0.0%
0 0 0 0 0 0 0 1 1 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0% 0.7% 0.0%
0 0 0 0 0 0 0 1 1 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0% 0.7% 0.0%
0 0 0 0 0 0 0 1 1 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
*
†
‡
§
At least ACSSuT† 
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACT/S‡
At least ACSSuTAuCx§
At least ceftriaxone and nalidixic acid 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
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3. Shigella 
 
Table 32.  Frequency of Shigella species, 2011 
n (%)
Shigella sonnei 225 (76.8)
Shigella flexneri 58 (19.8)
Shigella boydii 9 (3.1)
Other 1 (0.3)
Total 293 (100)
Species 2011
 
 
 
Table 33.  Minimum inhibitory concentrations (MICs) and resistance of Shigella isolates to antimicrobial 
agents, 2011 (N=293) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.7 [0.1 - 2.4] 0.7 12.6 80.5 5.5 0.7
Kanamycin 0.0 0.0 [0.0 - 1.3] 100.0
Streptomycin N/A 87.7 [83.4 - 91.2] 12.3 38.6 49.1
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 16.7 2.0 [0.8 - 4.4] 2.0 5.8 53.2 20.1 16.7 1.7 0.3
Cephems Ceftiofur 0.0 1.7 [0.6 - 3.9] 11.6 74.7 7.8 4.1 0.3 1.4
Ceftriaxone 0.0 1.7 [0.6 - 3.9] 97.6 0.7 0.3 0.3 1.0
Macrolide Azithromycin N/A 3.1 [1.4 - 5.8] 0.3 1.7 1.7 7.8 11.6 68.3 5.1 0.3 3.1
Penicillins Ampicillin 0.7 33.8 [28.4 - 39.5] 6.8 47.8 9.9 1.0 0.7 0.3 33.4
Quinolones Ciprofloxacin 0.0 2.4 [1.0 - 4.9] 91.5 0.7 1.4 2.4 1.4 0.3 1.7 0.7
Nalidixic acid N/A 6.1 [3.7 - 9.5] 3.4 75.1 11.6 2.7 1.0 2.7 3.4
Cephems Cefoxitin 1.4 1.0 [0.2 - 3.0] 3.1 75.4 18.8 0.3 1.4 0.7 0.3
Folate pathway inhibitors Sulfisoxazole N/A 44.7 [38.9 - 50.6] 31.1 16.4 6.1 1.0 0.7 44.7
Trimethoprim-sulfamethoxazole N/A 66.9 [61.2 - 72.3] 7.5 1.7 1.7 10.2 11.9 15.4 51.5
Phenicols Chloramphenicol 0.3 12.3 [8.8 - 16.6] 16.4 66.2 4.8 0.3 2.4 9.9
Tetracyclines Tetracycline 1.0 40.6 [34.9 - 46.5] 58.4 1.0 10.2 30.4
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
Figure 11.  Antimicrobial resistance pattern for Shigella, 2011 
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Table 34.  Percentage and number of Shigella isolates resistant to antimicrobial agents, 2002–2011 
2002
620
2003
495
2004
316
2005
396
2006
402
2007
480
2008
551
2009
475
2010
411
2011
293
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
0.2%
1
0.0%
0
0.0%
0
1.0%
4
0.2%
1
0.8%
4
0.4%
2
0.6%
3
0.5%
2
0.7%
2
Kanamycin
(MIC ≥ 64)
0.8%
5
0.4%
2
0.0%
0
0.8%
3
0.0%
0
0.2%
1
0.5%
3
0.4%
2
0.0%
0
0.0%
0
Streptomycin
(MIC ≥ 64)
54.4%
337
57.0%
282
59.8%
189
68.7%
272
60.7%
244
73.3%
352
80.6%
444
89.1%
423
91.0%
374
87.7%
257
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
2.6%
16
1.4%
7
1.6%
5
1.0%
4
1.5%
6
0.4%
2
3.3%
18
2.1%
10
0.0%
0
2.0%
6
Ceftiofur
(MIC ≥ 8)
0.2%
1
0.2%
1
0.3%
1
0.5%
2
0.2%
1
0.0%
0
0.0%
0
0.6%
3
0.2%
1
1.7%
5
Ceftriaxone
(MIC ≥ 4)
0.2%
1
0.2%
1
0.3%
1
0.5%
2
0.2%
1
0.0%
0
0.0%
0
0.6%
3
0.2%
1
1.7%
5
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
3.1%          
9
Penicillins Ampicillin
(MIC ≥ 32)
76.6%
475
79.4%
393
77.5%
245
70.7%
280
62.4%
251
63.8%
306
62.4%
344
46.3%
220
40.9%
168
33.8%
99
Ciprofloxacin
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.2%
1
0.2%
1
0.7%
4
0.6%
3
1.7%
7
2.4%
7
Nalidixic Acid
(MIC ≥ 32)
1.6%
10
1.0%
5
1.6%
5
1.5%
6
3.5%
14
1.7%
8
1.6%
9
2.1%
10
4.4%
18
6.1%
18
Cefoxitin
(MIC ≥ 32)
0.3%
2
0.0%
0
0.3%
1
0.3%
1
0.0%
0
0.0%
0
0.0%
0
0.6%
3
0.0%
0
1.0%
3
Cephalothin
(MIC ≥ 32)
6.6%
41
9.3%
46
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
31.8%
197
33.9%
168
52.5%
166
57.6%
228
40.3%
162
25.8%
124
28.5%
157
30.5%
145
29.9%
123
44.7%
131
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
37.3%
231
38.6%
191
46.8%
148
53.3%
211
46.0%
185
25.8%
124
31.2%
172
40.4%
192
47.7%
196
66.9%
196
Phenicols Chloramphenicol
(MIC ≥ 32)
7.6%
47
8.5%
42
15.2%
48
10.9%
43
10.9%
44
8.3%
40
6.9%
38
9.3%
44
10.0%
41
12.3%
36
Tetracyclines Tetracycline
(MIC ≥ 16)
30.6%
190
29.1%
144
49.4%
156
38.4%
152
34.6%
139
25.6%
123
24.3%
134
29.5%
140
31.4%
129
40.6%
119
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 35.  Resistance patterns of Shigella isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
620 495 316 396 402 480 551 475 411 293
8.2% 8.5% 4.7% 4.5% 6.5% 7.1% 4.5% 4.0% 3.6% 4.4%
51 42 15 18 26 34 25 19 15 13
91.8% 91.5% 95.3% 95.5% 93.5% 92.9% 95.5% 96.0% 96.4% 95.6%
569 453 301 378 376 446 526 456 396 280
55.2% 57.8% 64.2% 72.0% 64.7% 65.4% 68.2% 68.0% 69.8% 74.4%
342 286 203 285 260 314 376 323 287 218
41.6% 40.2% 59.5% 58.6% 43.8% 27.7% 35.2% 36.4% 39.7% 51.2%
258 199 188 232 176 133 194 173 163 150
24.4% 24.8% 32.9% 19.4% 15.4% 11.7% 10.3% 13.3% 14.1% 22.2%
151 123 104 77 62 56 57 63 58 65
2.9% 3.6% 7.0% 4.8% 5.2% 4.6% 2.7% 6.5% 4.6% 9.9%
18 18 22 19 21 22 15 31 19 29
1.8% 3.2% 6.0% 4.0% 5.0% 3.8% 2.2% 5.9% 4.4% 6.1%
11 16 19 16 20 18 12 28 18 18
2.7% 3.6% 6.6% 6.3% 6.0% 4.0% 2.9% 6.7% 4.9% 7.8%
17 18 21 25 24 19 16 32 20 23
29.8% 33.7% 34.5% 35.6% 26.6% 12.9% 16.0% 17.5% 17.8% 25.9%
185 167 109 141 107 62 88 83 73 76
0.3% 0.8% 0.6% 0.5% 0.5% 0.8% 0.0% 0.2% 1.2% 2.4%
2 4 2 2 2 4 0 1 5 7
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
0.0% 0.2% 0.3% 0.3% 0.2% 0.0% 0.0% 0.0% 0.2% 1.4%
0 1 1 1 1 0 0 0 1 4
*
†
‡
§
¶
**
At least AT/S§
At least ANT/S¶
At least ACSSuTAuCx**
At least ceftriaxone and nalidixic acid 
resistant
CLSI: Clinical and Laboratory Standards Institute; starting in 2011, testing included nine classes with the addition of the macrolide azithromycin 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, nalidixic acid
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone
At least ACT/S‡
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
  
 
48 
Table 36.  Minimum inhibitory concentrations (MICs) and resistance of Shigella sonnei isolates to 
antimicrobial agents, 2011 (N=225) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.9 [0.1 - 3.2] 6.7 87.1 5.3 0.9
Kanamycin 0.0 0.0 [0.0 - 1.6] 100.0
Streptomycin N/A 95.6 [92.0 - 97.9] 4.4 44.4 51.1
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 10.2 2.7 [1.0 - 5.7] 0.9 0.9 63.6 21.8 10.2 2.2 0.4
Cephems Ceftiofur 0.0 1.8 [0.5 - 4.5] 2.7 82.7 8.4 4.4 0.4 1.3
Ceftriaxone 0.0 1.8 [0.5 - 4.5] 97.3 0.9 0.4 0.4 0.9
Macrolide Azithromycin N/A 0.9 [0.1 - 3.2] 1.3 5.8 85.3 6.7 0.9
Penicillins Ampicillin 0.9 27.6 [21.8 - 33.9] 0.9 57.3 12.4 0.9 0.9 0.4 27.1
Quinolones Ciprofloxacin 0.0 1.3 [0.3 - 3.8] 95.1 0.4 1.3 0.9 0.9 1.3
Nalidixic acid N/A 3.6 [1.5 - 6.9] 3.6 81.8 8.4 2.2 0.4 1.8 1.8
Cephems Cefoxitin 1.3 1.3 [0.3 - 3.8] 3.1 81.3 12.9 1.3 0.9 0.4
Folate pathway inhibitors Sulfisoxazole N/A 39.6 [33.1 - 46.3] 30.7 20.4 7.6 1.3 0.4 39.6
Trimethoprim-sulfamethoxazole N/A 68.9 [62.4 - 74.9] 1.3 0.4 0.9 12.9 15.6 20.0 48.9
Phenicols Chloramphenicol 0.0 2.7 [1.0 - 5.7] 8.9 83.6 4.9 0.4 2.2
Tetracyclines Tetracycline 0.9 29.8 [23.9 - 36.2] 69.3 0.9 11.1 18.7
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Figure 12.  Antimicrobial resistance pattern for Shigella sonnei, 2011
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Table 37.  Percentage and number of Shigella sonnei isolates resistant to antimicrobial agents, 2002–2011 
2002
536
2003
434
2004
241
2005
340
2006
321
2007
414
2008
494
2009
410
2010
337
2011
225
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
0.0%
0
0.0%
0
1.2%
4
0.0%
0
1.0%
4
0.4%
2
0.7%
3
0.0%
0
0.9%
2
Kanamycin
(MIC ≥ 64)
0.4%
2
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.2%
1
0.6%
3
0.2%
1
0.0%
0
0.0%
0
Streptomycin
(MIC ≥ 64)
55.4%
297
56.5%
245
56.8%
137
70.3%
239
61.7%
198
76.8%
318
82.4%
407
91.5%
375
96.1%
324
95.6%
215
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
2.2%
12
1.4%
6
1.7%
4
1.2%
4
1.9%
6
0.5%
2
3.2%
16
2.0%
8
0.0%
0
2.7%
6
Ceftiofur
(MIC ≥ 8)
0.0%
0
0.0%
0
0.4%
1
0.6%
2
0.0%
0
0.0%
0
0.0%
0
0.5%
2
0.3%
1
1.8%
4
Ceftriaxone
(MIC ≥ 4)
0.0%
0
0.0%
0
0.4%
1
0.6%
2
0.0%
0
0.0%
0
0.0%
0
0.5%
2
0.3%
1
1.8%
4
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.9%
2
Penicillins Ampicillin
(MIC ≥ 32)
77.6%
416
79.7%
346
79.3%
191
70.6%
240
62.6%
201
64.0%
265
61.3%
303
43.2%
177
36.8%
124
27.6%
62
Ciprofloxacin
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.6%
3
0.0%
0
1.5%
5
1.3%
3
Nalidixic Acid
(MIC ≥ 32)
1.5%
8
0.5%
2
1.7%
4
1.2%
4
2.8%
9
1.2%
5
1.6%
8
1.7%
7
3.3%
11
3.6%
8
Cefoxitin
(MIC ≥ 32)
0.4%
2
0.0%
0
0.4%
1
0.3%
1
0.0%
0
0.0%
0
0.0%
0
0.7%
3
0.0%
0
1.3%
3
Cephalothin
(MIC ≥ 32)
7.3%
39
10.1%
44
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
29.9%
160
31.3%
136
49.0%
118
57.9%
197
33.3%
107
20.0%
83
24.5%
121
23.9%
98
25.2%
85
39.6%
89
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
37.9%
203
38.5%
167
46.9%
113
55.0%
187
42.7%
137
22.0%
91
29.1%
144
36.1%
148
46.9%
158
68.9%
155
Phenicols Chloramphenicol
(MIC ≥ 32)
0.2%
1
1.2%
5
2.5%
6
2.4%
8
0.9%
3
1.2%
5
0.8%
4
1.2%
5
1.5%
5
2.7%
6
Tetracyclines Tetracycline
(MIC ≥ 16)
23.5%
126
22.1%
96
36.1%
87
29.4%
100
22.7%
73
16.2%
67
16.8%
83
20.7%
85
21.4%
72
29.8%
67
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 38.  Resistance patterns of Shigella sonnei isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
536 434 241 340 321 414 494 410 337 225
7.1% 8.5% 5.4% 4.4% 6.2% 6.8% 4.7% 3.7% 1.5% 0.9%
38 37 13 15 20 28 23 15 5 2
92.9% 91.5% 94.6% 95.6% 93.8% 93.2% 95.3% 96.3% 98.5% 99.1%
498 397 228 325 301 386 471 395 332 223
51.9% 54.1% 56.4% 70.6% 59.8% 63.0% 65.4% 65.4% 68.0% 73.8%
278 235 136 240 192 261 323 268 229 166
36.6% 35.3% 51.0% 55.3% 35.8% 21.3% 29.4% 29.8% 32.6% 44.9%
196 153 123 188 115 88 145 122 110 101
19.8% 20.5% 25.7% 12.4% 8.1% 5.1% 5.3% 5.9% 6.5% 13.3%
106 89 62 42 26 21 26 24 22 30
0.7% 0.5% 0.8% 0.9% 0.0% 1.2% 0.4% 0.5% 0.6% 3.6%
4 2 2 3 0 5 2 2 2 8
0.0% 0.2% 0.0% 0.3% 0.0% 0.5% 0.2% 0.0% 0.6% 0.4%
0 1 0 1 0 2 1 0 2 1
0.2% 0.9% 1.7% 2.4% 0.9% 0.5% 0.8% 1.0% 0.9% 2.2%
1 4 4 8 3 2 4 4 3 5
30.2% 33.6% 35.3% 35.6% 22.7% 9.4% 14.2% 12.2% 14.2% 22.2%
162 146 85 121 73 39 70 50 48 50
0.2% 0.2% 0.8% 0.3% 0.0% 0.7% 0.0% 0.0% 0.0% 1.3%
1 1 2 1 0 3 0 0 0 3
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.4% 0.3% 0.0% 0.0% 0.0% 0.0% 0.3% 1.3%
0 0 1 1 0 0 0 0 1 3
*
†
‡
§
¶
**
At least ACT/S‡
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
At least AT/S§
At least ANT/S¶
At least ACSSuTAuCx**
At least ceftriaxone and nalidixic acid 
resistant
CLSI: Clinical and Laboratory Standards Institute; starting in 2011, testing included nine classes with the addition of the macrolide azithromycin 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, nalidixic acid
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone
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Table 39.  Minimum inhibitory concentrations and resistance of Shigella flexneri isolates to antimicrobial 
agents, 2011 (N=58) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 6.2] 3.4 31.0 58.6 6.9
Kanamycin 0.0 0.0 [0.0 - 6.2] 100.0
Streptomycin N/A 58.6 [44.9 - 71.4] 41.4 19.0 39.7
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 43.1 0.0 [0.0 - 6.2] 5.2 24.1 13.8 13.8 43.1
Cephems Ceftiofur 0.0 1.7 [0.0 - 9.2] 39.7 48.3 6.9 3.4 1.7
Ceftriaxone 0.0 1.7 [0.0 - 9.2] 98.3 1.7
Macrolide Azithromycin N/A 10.3 [3.9 - 21.2] 1.7 8.6 8.6 29.3 27.6 12.1 1.7 10.3
Penicillins Ampicillin 0.0 60.3 [46.6 - 73.0] 25.9 12.1 1.7 60.3
Quinolones Ciprofloxacin 0.0 6.9 [1.9 - 16.7] 81.0 1.7 1.7 3.4 3.4 1.7 3.4 3.4
Nalidixic acid N/A 12.1 [5.0 - 23.3] 1.7 56.9 20.7 5.2 3.4 3.4 8.6
Cephems Cefoxitin 1.7 0.0 [0.0 - 6.2] 1.7 53.4 41.4 1.7 1.7
Folate pathway inhibitors Sulfisoxazole N/A 60.3 [46.6 - 73.0] 32.8 3.4 1.7 1.7 60.3
Trimethoprim-sulfamethoxazole N/A 58.6 [44.9 - 71.4] 29.3 6.9 5.2 58.6
Phenicols Chloramphenicol 1.7 50.0 [36.6 - 63.4] 36.2 6.9 5.2 1.7 10.3 39.7
Tetracyclines Tetracycline 1.7 79.3 [66.6 - 88.8] 19.0 1.7 6.9 72.4
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Figure 13.  Antimicrobial resistance pattern for Shigella flexneri, 2011 
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Table 40.  Percentage and number of Shigella flexneri isolates resistant to antimicrobial agents, 2002–
2011 
2002
73
2003
51
2004
62
2005
52
2006
74
2007
61
2008
49
2009
57
2010
61
2011
58
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
1.4%
1
0.0%
0
0.0%
0
0.0%
0
1.4%
1
0.0%
0
0.0%
0
0.0%
0
3.3%
2
0.0%
0
Kanamycin
(MIC ≥ 64)
4.1%
3
3.9%
2
0.0%
0
3.8%
2
0.0%
0
0.0%
0
0.0%
0
1.8%
1
0.0%
0
0.0%
0
Streptomycin
(MIC ≥ 64)
43.8%
32
60.8%
31
71.0%
44
57.7%
30
58.1%
43
52.5%
32
63.3%
31
73.7%
42
68.9%
42
58.6%
34
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
5.5%
4
2.0%
1
1.6%
1
0.0%
0
0.0%
0
0.0%
0
4.1%
2
3.5%
2
0.0%
0
0.0%
0
Ceftiofur
(MIC ≥ 8)
1.4%
1
2.0%
1
0.0%
0
0.0%
0
1.4%
1
0.0%
0
0.0%
0
1.8%
1
0.0%
0
1.7%
1
Ceftriaxone
(MIC ≥ 4)
1.4%
1
2.0%
1
0.0%
0
0.0%
0
1.4%
1
0.0%
0
0.0%
0
1.8%
1
0.0%
0
1.7%
1
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
10.3%
6
Penicillins Ampicillin
(MIC ≥ 32)
75.3%
55
84.3%
43
80.6%
50
75.0%
39
63.5%
47
63.9%
39
75.5%
37
70.2%
40
67.2%
41
60.3%
35
Ciprofloxacin
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.4%
1
1.6%
1
2.0%
1
3.5%
2
3.3%
2
6.9%
4
Nalidixic Acid
(MIC ≥ 32)
2.7%
2
5.9%
3
1.6%
1
3.8%
2
5.4%
4
4.9%
3
2.0%
1
3.5%
2
11.5%
7
12.1%
7
Cefoxitin
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Cephalothin
(MIC ≥ 32)
2.7%
2
3.9%
2
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
41.1%
30
52.9%
27
66.1%
41
55.8%
29
68.9%
51
62.3%
38
63.3%
31
73.7%
42
55.7%
34
60.3%
35
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
28.8%
21
39.2%
20
46.8%
29
44.2%
23
59.5%
44
49.2%
30
49.0%
24
68.4%
39
55.7%
34
58.6%
34
Phenicols Chloramphenicol
(MIC ≥ 32)
63.0%
46
68.6%
35
61.3%
38
65.4%
34
54.1%
40
55.7%
34
65.3%
32
66.7%
38
55.7%
34
50.0%
29
Tetracyclines Tetracycline
(MIC ≥ 16)
78.1%
57
82.4%
42
95.2%
59
94.2%
49
83.8%
62
83.6%
51
87.8%
43
87.7%
50
86.9%
53
79.3%
46
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 41.  Resistance patterns of Shigella flexneri isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
73 51 62 52 74 61 49 57 61 58
15.1% 7.8% 0.0% 5.8% 5.4% 9.8% 4.1% 5.3% 9.8% 17.2%
11 4 0 3 4 6 2 3 6 10
84.9% 92.2% 100.0% 94.2% 94.6% 90.2% 95.9% 94.7% 90.2% 82.8%
62 47 62 49 70 55 47 54 55 48
76.7% 86.3% 93.5% 80.8% 85.1% 80.3% 93.9% 86.0% 83.6% 77.6%
56 44 58 42 63 49 46 49 51 45
75.3% 80.4% 90.3% 78.8% 75.7% 68.9% 85.7% 82.5% 80.3% 72.4%
55 41 56 41 56 42 42 47 49 42
57.5% 62.7% 64.5% 65.4% 47.3% 55.7% 57.1% 63.2% 57.4% 56.9%
42 32 40 34 35 34 28 36 35 33
19.2% 31.4% 29.0% 30.8% 28.4% 27.9% 26.5% 49.1% 27.9% 32.8%
14 16 18 16 21 17 13 28 17 19
15.1% 29.4% 27.4% 28.8% 27.0% 26.2% 22.4% 47.4% 26.2% 27.6%
11 15 17 15 20 16 11 27 16 16
21.9% 27.5% 24.2% 32.7% 28.4% 26.2% 24.5% 47.4% 27.9% 29.3%
16 14 15 17 21 16 12 27 17 17
27.4% 37.3% 35.5% 38.5% 43.2% 36.1% 32.7% 52.6% 41.0% 41.4%
20 19 22 20 32 22 16 30 25 24
1.4% 5.9% 0.0% 1.9% 2.7% 1.6% 0.0% 1.8% 8.2% 5.2%
1 3 0 1 2 1 0 1 5 3
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
0.0% 2.0% 0.0% 0.0% 1.4% 0.0% 0.0% 0.0% 0.0% 1.7%
0 1 0 0 1 0 0 0 0 1
*
†
‡
§
¶
**
At least AT/S§
At least ANT/S¶
At least ACSSuTAuCx**
At least ceftriaxone and nalidixic acid 
resistant
CLSI: Clinical and Laboratory Standards Institute; starting in 2011, testing included nine classes with the addition of the macrolide azithromycin 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, nalidixic acid
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone
At least ACT/S‡
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
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4. Escherichia coli O157 
 
Table 42.  Minimum inhibitory concentrations (MICs) and resistance of Escherichia coli O157 isolates to 
antimicrobial agents, 2011 (N=162)  
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.6 [0.0 - 3.4] 4.3 77.8 16.7 0.6 0.6
Kanamycin 0.0 1.9 [0.4 - 5.3] 98.1 1.9
Streptomycin N/A 4.3 [1.7 - 8.7] 95.7 1.2 3.1
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.6 0.0 [0.0 - 2.3] 2.5 7.4 87.0 2.5 0.6
Cephems Ceftiofur 0.0 0.0 [0.0 - 2.3] 1.2 7.4 90.1 1.2
Ceftriaxone 0.0 0.0 [0.0 - 2.3] 100.0
Macrolide Azithromycin N/A 0.0 [0.0 - 2.3] 6.2 82.1 9.9 0.6 1.2
Penicillins Ampicillin 0.0 3.7 [1.4 - 7.9] 4.9 80.9 10.5 3.7
Quinolones Ciprofloxacin 0.0 0.6 [0.0 - 3.4] 98.8 0.6 0.6
Nalidixic acid N/A 1.2 [0.1 - 4.4] 2.5 88.9 7.4 1.2
Cephems Cefoxitin 1.2 0.0 [0.0 - 2.3] 3.7 4.9 74.1 16.0 1.2
Folate pathway inhibitors Sulfisoxazole N/A 4.9 [2.2 - 9.5] 71.0 19.1 4.9 4.9
Trimethoprim-sulfamethoxazole N/A 2.5 [0.7 - 6.2] 96.9 0.6 2.5
Phenicols Chloramphenicol 0.6 1.2 [0.1 - 4.4] 1.2 21.0 75.9 0.6 1.2
Tetracyclines Tetracycline 0.0 4.9 [2.2 - 9.5] 95.1 0.6 4.3
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Figure 14.  Antimicrobial resistance pattern for Escherichia coli O157, 2011 
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Table 43.  Percentage and number of Escherichia coli O157 isolates resistant to antimicrobial agents, 
2002–2011 
2002
399
2003
158
2004
169
2005
194
2006
233
2007
190
2008
161
2009
187
2010
170
2011
162
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
0.0%
0
0.6%
1
0.5%
1
0.0%
0
0.0%
0
1.2%
2
0.5%
1
0.6%
1
0.6%
1
Kanamycin
(MIC ≥ 64)
0.5%
2
0.0%
0
0.0%
0
0.5%
1
0.4%
1
0.0%
0
0.0%
0
0.5%
1
1.2%
2
1.9%
3
Streptomycin
(MIC ≥ 64)
2.3%
9
1.9%
3
1.8%
3
2.1%
4
2.6%
6
2.1%
4
1.9%
3
4.8%
9
2.4%
4
4.3%
7
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
0.0%
0
1.3%
2
0.0%
0
0.0%
0
1.3%
3
0.5%
1
0.6%
1
0.5%
1
0.0%
0
0.0%
0
Ceftiofur
(MIC ≥ 8)
0.0%
0
1.3%
2
0.0%
0
0.0%
0
1.3%
3
0.0%
0
0.6%
1
0.0%
0
0.0%
0
0.0%
0
Ceftriaxone
(MIC ≥ 4)
0.0%
0
1.3%
2
0.0%
0
0.0%
0
1.3%
3
0.0%
0
0.6%
1
0.0%
0
0.0%
0
0.0%
0
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
1.5%
6
3.2%
5
1.2%
2
4.1%
8
2.6%
6
2.1%
4
3.7%
6
4.3%
8
1.8%
3
3.7%
6
Ciprofloxacin
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.4%
1
0.5%
1
0.0%
0
0.5%
1
0.0%
0
0.6%
1
Nalidixic Acid
(MIC ≥ 32)
1.0%
4
0.6%
1
1.8%
3
1.5%
3
2.1%
5
2.1%
4
1.2%
2
2.1%
4
1.2%
2
1.2%
2
Cefoxitin
(MIC ≥ 32)
0.0%
0
1.3%
2
0.6%
1
0.0%
0
1.3%
3
0.0%
0
1.2%
2
0.5%
1
0.0%
0
0.0%
0
Cephalothin
(MIC ≥ 32)
1.5%
6
3.2%
5
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Sulfamethoxazole/Sulfisoxazole‡
(MIC ≥ 512)
3.5%
14
3.8%
6
1.8%
3
6.7%
13
3.0%
7
2.6%
5
3.1%
5
6.4%
12
4.7%
8
4.9%
8
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
0.5%
2
0.6%
1
0.0%
0
0.5%
1
0.4%
1
1.1%
2
1.2%
2
4.3%
8
1.2%
2
2.5%
4
Phenicols Chloramphenicol
(MIC ≥ 32)
1.3%
5
1.3%
2
0.6%
1
1.0%
2
1.3%
3
0.5%
1
0.6%
1
1.1%
2
0.6%
1
1.2%
2
Tetracyclines Tetracycline
(MIC ≥ 16)
3.0%
12
5.7%
9
1.8%
3
8.8%
17
4.7%
11
4.7%
9
1.9%
3
7.5%
14
4.7%
8
4.9%
8
 *  Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004
Year
Total Isolates
I
Aminoglycosides
Cephems
Quinolones
II
Cephems
Folate pathway inhibitors
 
 
 
Table 44.  Resistance patterns of Escherichia coli O157 isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
399 158 169 194 233 190 161 187 170 162
94.0% 90.5% 94.7% 87.6% 91.8% 92.1% 91.9% 89.8% 93.5% 92.6%
375 143 160 170 214 175 148 168 159 150
6.0% 9.5% 5.3% 12.4% 8.2% 7.9% 8.1% 10.2% 6.5% 7.4%
24 15 9 24 19 15 13 19 11 12
3.8% 5.1% 2.4% 6.7% 4.7% 3.2% 3.1% 7.5% 4.7% 4.9%
15 8 4 13 11 6 5 14 8 8
2.0% 3.2% 1.2% 5.2% 3.4% 2.1% 2.5% 5.9% 4.1% 4.3%
8 5 2 10 8 4 4 11 7 7
0.8% 1.3% 0.6% 1.0% 2.1% 1.1% 1.2% 4.3% 1.8% 2.5%
3 2 1 2 5 2 2 8 3 4
0.0% 0.0% 0.0% 0.0% 0.9% 0.5% 0.0% 0.5% 0.0% 0.6%
0 0 0 0 2 1 0 1 0 1
0.0% 0.0% 0.0% 0.0% 0.9% 0.0% 0.0% 0.0% 0.0% 0.6%
0 0 0 0 2 0 0 0 0 1
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.6% 0.0% 0.0% 1.2%
0 0 0 0 0 0 1 0 0 2
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 1 0 0 0 0 0
*
†
‡
§
At least ACSSuTAuCx§
At least ceftriaxone and nalidixic acid 
resistant
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
At least ACT/S‡
CLSI: Clinical and Laboratory Standards Institute; starting in 2011, testing included nine classes with the addition of the macrolide azithromycin
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
Resistance ≥ 1 CLSI class*
Year
Total Isolates
Resistance Pattern
No resistance detected 
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5. Campylobacter 
 
Table 45.  Frequency of Campylobacter species, 2011 
N (%)
Campylobacter jejuni 1275 (86.3)
Campylobacter coli 148 (10.0)
Other 55 (3.7)
Total 1478 (100)
Species 2011
 
 
 
 
Table 46.  Minimum inhibitory concentrations (MICs) and resistance of Campylobacter isolates to 
antimicrobial agents, 2011 (N=1478) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.1 2.0 [1.4 - 2.9] 3.4 33.2 57.8 3.3 0.3 0.1 0.1 2.0
Ketolide Telithromycin 1.4 2.1 [1.4 - 3.0] 0.1 0.1 1.6 10.1 34.9 37.7 12.0 1.4 2.1
Macrolides Azithromycin 0.0 1.8 [1.2 - 2.6] 1.5 10.1 46.2 35.6 4.3 0.2 0.3 1.8
Erythromycin 0.0 1.8 [1.2 - 2.6] 0.3 2.0 14.6 49.3 26.1 5.5 0.4 1.8
Quinolones Ciprofloxacin 0.3 24.2 [22.0 - 26.4] 0.4 17.6 43.5 10.4 3.2 0.5 0.3 0.6 7.1 9.7 4.7 1.6 0.5
Nalidixic acid 0.3 24.8 [22.6 - 27.0] 56.7 15.2 3.0 0.3 0.4 24.4
Lincosamides Clindamycin 0.3 2.0 [1.4 - 2.9] 0.1 3.8 28.1 43.4 17.9 4.4 0.3 0.3 0.3 1.4
Phenicols Florfenicol†† N/A 2.0 [1.4 - 2.9] 0.1 0.8 25.4 59.4 12.2 1.4 0.5 0.1
Tetracyclines Tetracycline 0.1 45.1 [42.5 - 47.6] 0.1 2.4 24.2 18.9 6.5 1.9 0.9 0.1 0.2 0.4 1.6 42.8
*
†
‡
§
¶
**
††
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages 
of isolates w ith MICs equal to or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Only a susceptible breakpoint (≤ 4 μg/mL) has been established. In this report, isolates w ith an MIC ≥ 8 μg/mL are categorized as resistant.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 15.  Antimicrobial resistance pattern for Campylobacter, 2011 
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Table 47.  Percentage and number of Campylobacter isolates resistant to antimicrobial agents, 2002–2011 
2002
354
2003
328
2004
347
2005
888
2006
816
2007
1100
2008
1155
2009
1495
2010
1310
2011
1478
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Gentamicin
(MIC ≥ 8)
0.0%
0
0.3%
1
0.3%
1
0.5%
4
0.1%
1
0.6%
7
1.1%
13
0.9%
13
1.6%
21
2.0%
30
Ketolides Telithromycin
(MIC ≥ 16)
Not
Tested
Not
Tested
Not
Tested
1.0%
9
1.6%
13
1.5%
16
2.5%
29
1.5%
22
1.6%
21
2.1%
31
Azithromycin
(MIC ≥ 8)
2.0%
7
0.9%
3
0.6%
2
1.8%
16
1.7%
14
2.0%
22
3.0%
35
1.7%
25
1.5%
19
1.8%
27
Erythromycin
(MIC ≥ 32)
1.4%
5
0.9%
3
0.3%
1
1.7%
15
1.7%
14
2.0%
22
3.0%
35
1.7%
25
1.5%
19
1.8%
27
Ciprofloxacin
(MIC ≥ 4)
20.1%
71
17.7%
58
19.0%
66
21.6%
192
19.6%
160
26.0%
286
23.0%
266
22.9%
342
22.4%
294
24.2%
357
Nalidixic Acid
(MIC ≥ 64)
20.6%
73
18.9%
62
19.6%
68
22.3%
198
20.1%
164
26.5%
291
23.5%
272
23.1%
346
22.7%
298
24.8%
366
Lincosamides Clindamycin
(MIC ≥ 8)
2.0%
7
0.6%
2
2.0%
7
1.4%
12
2.0%
16
1.7%
19
2.8%
32
1.4%
21
1.7%
22
2.0%
30
Phenicols Chloramphenicol
(MIC ≥ 32)
0.3%
1
0.0%
0
1.4%
5
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Florfenicol‡
Susceptible breakpoint: (MIC ≤ 4)
Not
Tested
Not
Tested
Not
Tested
0.5%
4
0.0%
0
0.0%
0
0.5%
6
0.5%
8
1.3%
17
2.0%
30
Tetracyclines Tetracycline
(MIC ≥ 16)
41.2%
146
38.4%
126
46.1%
160
40.5%
360
46.0%
375
44.4%
488
43.6%
504
43.5%
651
42.1%
552
45.1%
666
 *   Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Only a susceptible breakpoint (≤ 4 μg/mL) has been established. In this report, isolates with an MIC ≥ 8 μg/mL are categorized as resistant.
Year
Total Isolates
I
Macrolides
Quinolones
II
 
 
 
Table 48.  Resistance patterns of Campylobacter isolates, 2002–2011
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
354 328 347 888 816 1100 1155 1495 1310 1478
48.0% 50.9% 46.1% 48.5% 43.9% 45.2% 45.9% 46.4% 47.3% 45.0%
170 167 160 431 358 497 530 694 619 665
52.0% 49.1% 53.9% 51.5% 56.1% 54.8% 54.1% 53.6% 52.7% 55.0%
184 161 187 457 458 603 625 801 691 813
12.7% 8.5% 14.1% 13.6% 12.0% 17.5% 15.6% 14.2% 14.3% 17.4%
45 28 49 121 98 192 180 212 187 257
1.4% 0.9% 1.7% 1.7% 1.5% 1.7% 2.7% 1.7% 2.1% 3.0%
5 3 6 15 12 19 31 25 28 45
0.0% 0.3% 0.3% 0.3% 0.5% 0.9% 1.4% 1.1% 0.8% 1.2%
0 1 1 3 4 10 16 16 10 18
0.0% 0.3% 0.0% 0.0% 0.1% 0.6% 0.7% 0.5% 0.6% 0.7%
0 1 0 0 1 7 8 8 8 11
0.8% 0.9% 0.6% 1.0% 0.9% 1.4% 1.7% 1.2% 0.9% 1.7%
3 3 2 9 7 15 20 18 12 25
* CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Resistance Pattern
No resistance detected 
 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
At least quinolone and macrolide resistant
Resistance ≥ 5 CLSI classes*
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Table 49.  Minimum inhibitory concentrations (MICs) and resistance of Campylobacter jejuni isolates to 
antimicrobial agents, 2011 (N=1275) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin < 0.1 0.9 [0.5 - 1.6] 3.4 33.7 59.1 2.7 0.2 < 0.1 0.9
Ketolide Telithromycin 0.7 1.9 [1.2 - 2.8] < 0.1 0.9 8.5 38.0 40.0 10.0 0.7 1.9
Macrolides Azithromycin 0.0 1.7 [1.1 - 2.6] 1.6 10.4 47.7 35.4 3.1 0.2 1.7
Erythromycin 0.0 1.7 [1.1 - 2.6] 0.3 1.8 13.7 52.2 26.2 3.9 < 0.1 1.7
Quinolones Ciprofloxacin 0.2 23.5 [21.1 - 25.9] 0.4 19.5 45.3 9.1 1.6 0.4 0.2 0.6 7.2 9.5 4.2 1.3 0.6
Nalidixic acid 0.4 23.7 [21.4 - 26.1] 61.5 12.6 1.8 0.4 0.3 23.4
Lincosamides Clindamycin 0.2 1.8 [1.1 - 2.7] 0.2 3.8 29.2 45.4 15.9 3.5 0.2 0.2 0.3 1.3
Phenicols Florfenicol†† N/A 2.1 [1.4 - 3.1] < 0.1 0.9 27.0 60.1 9.9 1.4 0.6 < 0.1
Tetracyclines Tetracycline 0.2 45.9 [43.1 - 48.7] 0.2 2.4 24.8 18.3 6.1 1.3 0.9 0.2 < 0.1 0.5 1.8 43.5
*
†
‡
§
¶
**
††
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages 
of isolates w ith MICs equal to or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Only a susceptible breakpoint (≤ 4 μg/mL) has been established. In this report, isolates w ith an MIC ≥ 8 μg/mL are categorized as resistant.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 16.  Antimicrobial resistance pattern for Campylobacter jejuni, 2011 
 
 
 
 
 
Table 50.  Percentage and number of Campylobacter jejuni isolates resistant to antimicrobial agents, 
2002–2011 
2002
329
2003
303
2004
320
2005
788
2006
709
2007
992
2008
1042
2009
1350
2010
1158
2011
1275
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Gentamicin
(MIC ≥ 8)
0.0%
0
0.0%
0
0.3%
1
0.1%
1
0.0%
0
0.7%
7
1.1%
11
0.6%
8
0.6%
7
0.9%
12
Ketolides Telithromycin
(MIC ≥ 16)
Not
Tested
Not
Tested
Not
Tested
0.5%
4
0.8%
6
1.0%
10
2.1%
22
1.3%
18
1.2%
14
1.9%
24
Azithromycin
(MIC ≥ 8)
1.8%
6
0.3%
1
0.6%
2
1.5%
12
0.8%
6
1.6%
16
2.2%
23
1.5%
20
1.1%
13
1.7%
22
Erythromycin
(MIC ≥ 32)
1.2%
4
0.3%
1
0.3%
1
1.4%
11
0.8%
6
1.6%
16
2.2%
23
1.5%
20
1.1%
13
1.7%
22
Ciprofloxacin
(MIC ≥ 4)
20.7%
68
17.2%
52
18.1%
58
21.3%
168
19.5%
138
25.8%
256
22.3%
232
23.0%
310
21.8%
252
23.5%
299
Nalidixic Acid
(MIC ≥ 64)
21.3%
70
17.8%
54
18.4%
59
21.7%
171
19.0%
135
26.1%
259
22.7%
237
23.1%
312
21.9%
254
23.7%
302
Lincosamides Clindamycin
(MIC ≥ 8)
1.8%
6
0.0%
0
2.2%
7
0.9%
7
1.0%
7
1.3%
13
2.0%
21
1.3%
17
1.2%
14
1.8%
23
Phenicols Chloramphenicol
(MIC ≥ 32)
0.3%
1
0.0%
0
1.6%
5
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Florfenicol‡
Susceptible breakpoint: (MIC ≤ 4)
Not
Tested
Not
Tested
Not
Tested
0.4%
3
0.0%
0
0.0%
0
0.6%
6
0.6%
8
1.5%
17
2.1%
27
Tetracyclines Tetracycline
(MIC ≥ 16)
41.3%
136
38.3%
116
46.9%
150
41.8%
329
47.4%
336
44.8%
444
44.1%
460
43.4%
586
42.7%
495
45.9%
585
 *   Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Only a susceptible breakpoint (≤ 4 μg/mL) has been established. In this report, isolates with an MIC ≥ 8 μg/mL are categorized as resistant.
Year
Total Isolates
I
Macrolides
Quinolones
II
  
 
Gentamicin 
Telithromycin 
Azithromycin 
Erythromycin 
Ciprofloxacin 
Nalidixic acid 
Clindamycin 
Florfenicol 
Tetracycline 
Antimicrobial 
Agent Susceptible, Intermediate, and Resistant Proportion 
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Table 51.  Minimum inhibitory concentrations (MICs) and resistance of Campylobacter coli isolates to 
antimicrobial agents, 2011 (N=148) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 12.2 [7.4 - 18.5] 23.6 62.2 1.4 0.7 0.7 11.5
Ketolide Telithromycin 7.4 3.4 [1.1 - 7.7] 1.4 8.1 23.6 8.1 20.3 27.7 7.4 3.4
Macrolides Azithromycin 0.0 2.7 [0.7 - 6.8] 0.7 6.8 33.1 37.8 16.2 2 0.7 2.7
Erythromycin 0.0 2.7 [0.7 - 6.8] 3.4 22.3 23.6 25.7 18.9 3.4 2.7
Quinolones Ciprofloxacin 0.0 35.8 [28.1 - 44.1] 0.7 3.4 30.4 17.6 11.5 0.7 7.4 14.9 9.5 4.1
Nalidixic acid 0.0 35.8 [28.1 - 44.1] 18.9 36.5 8.8 35.8
Lincosamides Clindamycin 0.7 4.1 [1.5 - 8.6] 2.0 21.6 31.1 28.4 12.2 0.7 1.4 2.7
Phenicols Florfenicol†† N/A 0.7 [0.0 - 3.7] 0.7 15.5 58.1 25 0.7
Tetracyclines Tetracycline 0.0 50.7 [42.3 - 59.0] 1.4 17.6 20.9 6.8 2.7 1.4 0.7 48.6
*
†
‡
§
¶
**
††
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages 
of isolates w ith MICs equal to or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Only a susceptible breakpoint (≤ 4 μg/mL has been established. In this report, isolates w ith an MIC ≥ 8 μg/mL are categorized as resistant.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 17.  Antimicrobial resistance pattern for Campylobacter coli, 2011 
 
 
 
 
 
Table 52.  Percentage and number of Campylobacter coli isolates resistant to antimicrobial agents, 2002–
2011 
2002
25
2003
22
2004
26
2005
99
2006
97
2007
105
2008
110
2009
142
2010
116
2011
148
Rank* CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Gentamicin
(MIC ≥ 8)
0.0%
0
4.5%
1
0.0%
0
3.0%
3
1.0%
1
0.0%
0
1.8%
2
3.5%
5
12.1%
14
12.2%
18
Ketolides Telithromycin
(MIC ≥ 16)
Not
Tested
Not
Tested
Not
Tested
5.1%
5
7.2%
7
5.7%
6
6.4%
7
2.8%
4
5.2%
6
3.4%
5
Azithromycin
(MIC ≥ 8)
4.0%
1
9.1%
2
0.0%
0
4.0%
4
8.2%
8
5.7%
6
10.9%
12
3.5%
5
5.2%
6
2.7%
4
Erythromycin
(MIC ≥ 32)
4.0%
1
9.1%
2
0.0%
0
4.0%
4
8.2%
8
5.7%
6
10.9%
12
3.5%
5
5.2%
6
2.7%
4
Ciprofloxacin
(MIC ≥ 4)
12.0%
3
22.7%
5
30.8%
8
24.2%
24
21.6%
21
28.6%
30
30.9%
34
22.5%
32
31.9%
37
35.8%
53
Nalidixic Acid
(MIC ≥ 64)
12.0%
3
22.7%
5
34.6%
9
27.3%
27
23.7%
23
30.5%
32
30.9%
34
23.9%
34
31.9%
37
35.8%
53
Lincosamides Clindamycin
(MIC ≥ 8)
4.0%
1
9.1%
2
0.0%
0
5.1%
5
9.3%
9
5.7%
6
10.0%
11
2.8%
4
6.9%
8
4.1%
6
Phenicols Chloramphenicol
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Florfenicol‡
Susceptible breakpoint: (MIC ≤ 4)
Not
Tested
Not
Tested
Not
Tested
1.0%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.7%
1
Tetracyclines Tetracycline
(MIC ≥ 16)
40.0%
10
45.5%
10
38.5%
10
31.3%
31
39.2%
38
41.9%
44
40.0%
44
45.1%
64
49.1%
57
50.7%
75
 *   Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
 † CLSI: Clinical and Laboratory Standards Institute 
 ‡ Only a susceptible breakpoint (≤ 4 μg/mL) has been established. In this report, isolates with an MIC ≥ 8 μg/mL are categorized as resistant.
Year
Total Isolates
I
Macrolides
Quinolones
II
  
 
Gentamicin 
Telithromycin 
Azithromycin 
Erythromycin 
Ciprofloxacin 
Nalidixic acid 
Clindamycin 
Florfenicol 
Tetracycline 
Antimicrobial 
Agent Susceptible, Intermediate, and Resistant Proportion 
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6. Vibrio species other than V. cholerae 
 
Table 53.  Frequency of Vibrio species other than V. cholerae, 2009–2011 
n (%) n (%) n (%)
Vibrio parahaemolyticus 149 (52.8) 179 (54.2) 201 (50.3)
Vibrio alginolyticus 46 (16.3) 49 (14.8) 103 (25.8)
Vibrio vulnificus 50 (17.7) 61 (18.5) 63 (15.8)
Vibrio fluvialis 21 (7.4) 24 (7.3) 18 (4.5)
Vibrio mimicus 11 (3.9) 9 (2.7) 9 (2.3)
Vibrio harveyi 0 (0) 2 (0.6) 4 (1.0)
Other 5 (1.8) 6 (1.8) 2 (0.5)
Total 282 (100) 330 (100) 400 (100)
Species 2009 2010 2011
 
 
 
 
Table 54.  Minimum inhibitory concentrations (MICs) and resistance of isolates of Vibrio species other 
than V. cholerae to antimicrobial agents, 2009–2011
CLSI† Antimicrobial Class
   Antimicrobial Agent Year (# of isolates) %I‡ %R§ [95% CI]¶ 0.002 0.004 0.007 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Aminoglycosides
   Kanamycin†† 2009 (282) N/A N/A N/A 0.4 5.7 55.7 34.0 4.3
2010 (330) N/A N/A N/A 0.6 7.0 60.0 30.9 0.9 0.6
2011 (400) N/A N/A N/A 0.5 1.3 39.5 50.3 7.3 1.0 0.3
   Streptomycin†† 2009 (282) N/A N/A N/A 2.5 9.9 39 47.2 1.4
2010 (330) N/A N/A N/A 0.9 2.7 9.4 55.8 30.6 0.6
2011 (400) N/A N/A N/A 3.8 41.0 52.0 3.0 0.3
Penicillins
   Ampicillin 2009 (282) 21.6 22.0 [17.3 - 27.3] 0.4 14.2 11.3 11.3 19.1 21.6 9.2 4.6 1.4 6.7
2010 (330) 16.7 19.1 [15.0 - 23.8] 0.9 14.8 10.3 19.1 19.1 16.7 6.7 3.0 0.6 8.8
2011 (400) 16.3 48.5 [43.5 - 53.5] 0.3 0.5 10.3 5.3 10.3 8.8 16.3 15.3 8.5 2.0 1.3 21.5
Quinolones
   Ciprofloxacin 2009 (282) 0.0 0.0 [0.0 - 1.3] 6.4 2.8 2.8 7.8 18.1 58.2 3.5 0.4
2010 (330) 0.0 0.0 [0.0 - 1.1] 5.2 4.5 1.2 9.7 16.1 57.6 4.8 0.9
2011 (400) 0.0 0.0 [0.0 - 0.9] 1.8 3.3 2.5 6.8 11.8 42.8 29.3 2.0
   Nalidixic acid†† 2009 (282) N/A N/A N/A 1.1 5.7 27.3 61.7 3.5 0.7
2010 (330) N/A N/A N/A 1.2 5.8 33.6 50.9 8.5
2011 (400) N/A N/A N/A 0.8 2.5 20.0 63.8 12.5 0.3 0.3
Cephems
   Cephalothin†† 2009 (282) N/A N/A N/A 0.7 2.8 5.0 19.1 59.6 7.8 0.7 4.3
2010 (330) N/A N/A N/A 0.6 2.7 12.1 50.0 28.2 0.6 5.8
2011 (400) N/A N/A N/A 0.3 3.0 4.5 30.5 50.5 7.5 0.3 3.5
Folate pathway inhibitors
   Trimethoprim-sulfamethoxazole 2009 (282) N/A 0.0 [0.0 - 1.3] 0.4 8.2 61.3 30.1
2010 (330) N/A 0.3 [0.0 - 1.7] 0.3 0.3 0.9 13.9 70.0 13.6 0.3 0.3 0.3
2011 (400) N/A 0.3 [0.0 - 1.4] 14.8 73.0 12.0 0.3
Phenicols
   Chloramphenicol†† 2009 (282) N/A N/A N/A 9.6 82.6 7.8
2010 (330) N/A N/A N/A 0.3 0.6 11.8 82.1 4.5 0.3 0.3
2011 (400) N/A N/A N/A 5.5 72 21.5 0.5 0.3 0.3
Tetracyclines
   Tetracycline 2009 (282) 0.0 0.0 [0.0 - 1.3] 1.1 0.7 5.7 44.0 48.2 0.4
2010 (330) 0.0 0.0 [0.0 - 1.1] 0.3 0.9 6.7 63.9 27.3 0.9
2011 (400) 0.0 0.3 [0.0 - 1.4] 0.3 1.0 9.0 70.3 17.8 1.5 0.3
*
†
‡
§
¶
**
††
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists or no CLSI breakpoints have been established
Percentage of isolates that w ere resistant; N/A indicates that no CLSI breakpoints have been established
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method; N/A indicates that no CLSI breakpoints have been established
The unshaded areas indicate the dilution range of the Etest® strips used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the shaded areas indicate 
the percentages of isolates w ith MICs greater than the highest concentrations on the Etest® strip. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to or less than the low est tested 
concentration. CLSI breakpoints w ere used w hen available.
CLSI MIC interpretive criteria have not been established
Rank*
Percentage of isolates Percentage of all isolates w ith MIC (µg/mL)**
I
II
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Table 55.  Percentage and number of isolates of Vibrio species other than V. cholerae resistant to 
ampicillin, 2009–2011 
Species 2009 2010 2011
Vibrio parahaemolyticus
9.4%
14
8.4%
15
40.3%
81
Vibrio alginolyticus
82.6%
38
89.8%
44
95.1%
98
Vibrio vulnificus
2.0%
1
0.0%
0
4.8%
3
Vibrio fluvialis
33.3%
7
12.5%
3
44.4%
8
Vibrio mimicus
9.1%
1
0.0%
0
0.0%
0
Vibrio harveyi
0.0%
0
50.0%
1
100.0%
4
Other
20.0%
1
0.0%
0
0.0%
0
Total
22.0%
62
19.1%
63
48.5%
194  
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The following figures display resistance to selected agents and combinations of agents from 1996–2011 for non-
typhoidal Salmonella, 1999–2011 for Salmonella ser. Typhi, 1997–2011 for Campylobacter, and 1999–2011 for 
Shigella. 
 
 
Figure 18.  Percentage of non-typhoidal Salmonella isolates resistant to nalidixic acid, by year, 1996–2011 
 
  
 
 Upper and lower limits of the individual 95% confidence intervals for annual percent resistant  
Annual percent resistant 
 
 
Upper and lower limits of the individual 95% confidence intervals for annual percentage resistant 
Annual percentage resistant 
Antimicrobial Resistance: 1996–2011 
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Figure 19.  Percentage of non-typhoidal Salmonella isolates resistant to ceftriaxone, by year, 1996–2011 
 
 
 
Figure 20.  Percentage of Salmonella ser. Enteritidis isolates resistant to nalidixic acid, by year, 1996–
2011 
 
  
 
 Upper and lower limits of the individual 95% confidence intervals for annual percent resistant  
Annual percent resistant 
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Figure 21.  Percentage of Salmonella ser. Heidelberg isolates resistant to ceftriaxone, by year, 1996–2011 
 
 
 
Figure 22.  Percentage of Salmonella ser. Typhimurium isolates resistant to at least ampicillin, 
chloramphenicol, streptomycin, sulfonamide, and tetracycline (ACSSuT), by year, 1996–2011 
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Figure 23.  Percentage of Salmonella ser. Newport isolates resistant to at least ampicillin, 
chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone 
(ACSSuTAuCx), by year, 1996–2011 
 
 
 
Figure 24.  Percentage of non-typhoidal Salmonella isolates resistant to 1 or more antimicrobial classes, 
by year, 1996–2011 
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Figure 25.  Percentage of non-typhoidal Salmonella isolates resistant to 3 or more antimicrobial classes, 
by year, 1996–2011 
 
 
 
Figure 26.  Percentage of Salmonella ser. Typhi isolates resistant to nalidixic acid, by year, 1999–2011 
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Figure 27.  Percentage of Campylobacter isolates resistant to ciprofloxacin, by year, 1997–2011 
 
 
 
Figure 28.  Percentage of Shigella isolates resistant to nalidixic acid, by year, 1999–2011 
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In 2011 the World Health Organization (WHO) convened a panel of experts to update a list of antimicrobial agents 
ranked according to their relative importance to human medicine (WHO, 2011).  The participants categorized 
antimicrobial agents as either Critically Important, Highly Important, or Important based upon two criteria: (1) used 
as sole therapy or one of the few alternatives to treat serious human disease and (2) used to treat disease caused 
by either organisms that may be transmitted via non–human sources or diseases caused by organisms that may 
acquire resistance genes from non–human sources  Antimicrobial agents tested in NARMS have been included in 
the WHO categorization table. 
 
 Antimicrobial agents are critically important if both criteria (1) and (2) are true. 
 Antimicrobial agents are highly important if either criterion (1) or (2) is true. 
 Antimicrobial agents are important if neither criterion is true. 
 
Table A1.  WHO categorization of antimicrobials of critical importance to human medicine 
WHO 
Category 
Level 
Importance CLSI* Class 
Antimicrobial Agent tested in 
NARMS 
I Critically important 
Aminoglycosides 
Amikacin 
Gentamicin 
Kanamycin 
Streptomycin 
β-lactam / β-lactamase inhibitor 
combinations 
Amoxicillin-clavulanic acid 
Piperacillin-tazobactam 
Cephems  
Cefepime 
Cefotaxime 
Ceftazidime 
Ceftriaxone 
Ketolides Telithromycin 
Macrolides 
Azithromycin 
Erythromycin 
Monobactams Aztreonam 
Penems Imipenem 
Penicillins Ampicillin 
Quinolones 
Ciprofloxacin 
Nalidixic acid 
    
II Highly important 
Cephems 
Cefoxitin 
Cephalothin 
Folate pathway inhibitors 
Sulfamethoxazole / Sulfisoxazole 
Trimethoprim-sulfamethoxazole 
Lincosamides Clindamycin 
Phenicols Chloramphenicol 
Tetracyclines Tetracycline 
 
* CLSI: Clinical and Laboratory Standards Institute 
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Repeat testing of an isolate must be done when one or more of the following conditions occur: 
 
 No growth on panel 
 Growth in all wells  
 Multiple skip patterns  
 Apparent contamination in wells or isolate preparation 
 Unlikely or discordant susceptibility results (Table B1) 
 
If an isolate is retested, data for all antimicrobial agents should be replaced with the new test results.   
Categorical changes may require a third test (and may indicate a mixed culture).   
 
Uncommon test results (Table B2) may represent emerging resistance phenotypes.  Retesting is encouraged.   
 
Table B1.  Retest criteria for unlikely or discordant resistance phenotypes 
Organism(s) Resistance phenotype (MIC values in µg/mL) Comments 
Salmonella and   
E. coli O157 
ceftiofur
R
 (≥8) OR ceftriaxone
R 
(≥4)
 
AND 
ampicillin
S 
(≤8) 
The presence of an ESBL
*
 or AmpC beta-
lactamase should confer resistance to ampicillin 
ceftiofur
R
 (≥8) AND ceftriaxone
S 
(≤1) OR 
ceftiofur
S
 (≤2) AND ceftriaxone
R 
(≥4)  
Both antimicrobial agents are 3
rd
 generation β-
lactams and should have equal susceptibility 
interpretations 
ampicillin
S
 (≤8) AND  
amoxicillin-clavulanic acid
R 
(≥32/16) 
 
sulfisoxazole
S
 (≤256) AND  
trimethoprim-sulfamethoxazole
R 
(≥4/76) 
 
Salmonella  nalidixic acid
S
 (≤16) AND 
ciprofloxacin
R 
(≥1) 
The stepwise selection of mutations in the QRDR
†  
does not support this phenotype, although it may 
occur with plasmid-mediated mechanisms 
E. coli O157 nalidixic acid
S
 (≤16) AND  
ciprofloxacin
R 
(≥4) 
The stepwise selection of mutations in the QRDR
†
 
does not support this phenotype 
Campylobacter erythromycin
S
 (≤8) AND  
azithromycin
R
 (≥8)  Erythromycin is class representative for 14- and 
15-membered macrolides (azithromycin, 
clarithromycin, roxithromycin, and dirithromycin) erythromycin
R 
 (≥32) AND  
azithromycin
S
 (≤2) 
nalidixic acid
S
 (≤16) AND  
ciprofloxacin
R
 (≥4)  In Campylobacter, one mutation is sufficient to 
confer resistance to both nalidixic acid and 
ciprofloxacin nalidixic acid
R
 (≥64) AND 
ciprofloxacin
S
 (≤1) 
For C. fetus and C. lari isolates: 
nalidixic Acid
S
 (≤16) OR ciprofloxicin
S 
(≤1) 
C. fetus and C. lari are intrinsically resistant to 
quinolones; consider likelihood of misidentification 
 
* Extended-spectrum beta-lactamase 
† Quinolone resistance-determining regions 
 
 
Table B2.  Uncommon resistance phenotypes for which retesting is encouraged 
Organism(s) Resistance phenotype (MIC values in µg/mL) 
Salmonella and   
E. coli O157 
Pan-resistance  
Resistance to azithromycin (>16) 
ceftriaxone and/or ceftiofur MIC ≥2 AND  
ciprofloxacin MIC ≥0.125 and/or nalidixic acid MIC ≥32 
Campylobacter Pan-resistance  
Resistance to gentamicin (≥8)  
Not susceptible to florfenicol (≥8) 
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